OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## OFFICE OF HEALTH ECONOMICS 


**----- Start of picture text -----**<br>
ohe.org<br>**----- End of picture text -----**<br>




**----- Start of picture text -----**<br>
0<br>**----- End of picture text -----**<br>




OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

2025 

## OFFICE OF HEALTH ECONOMICS Annual Charity Report 

## **Graham Cookson** 

Office of Health Economics, London 

**Mireia Jofre-Bonet** Office of Health Economics, London 

**Tim Watson** Office of Health Economics, London 

**Charlotte Ashton** 

Office of Health Economics, London 

**Claire Green** Office of Health Economics, London 

**Julia Toth** Office of Health Economics, London 

**Lishani Ramanayake** Office of Health Economics, London 

**Kelsey Moore** Office of Health Economics, London 

**Megan Skingle** Office of Health Economics, London 


**----- Start of picture text -----**<br>
1<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Table of contents 

|About OHE|3|
|---|---|
|Snapshot of the year|5|
|Charitable activities & impact|7|
|Strategic Research Themes|11|
|Project spotlights|20|
|Our growing global footprint|22|
|Our research outputs|24|
|Engagement &  dissemination|26|
|Financial Review|29|
|Grants & Contract Research|31|
|Structure, Governance & Management|34|
|Appendices|36|




**----- Start of picture text -----**<br>
2<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## About OHE 

Mission Support better health care policies by providing insightful economic and statistical analyses of critical issues. 

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE, and our governance is the responsibility of the Board of Trustees. 


**----- Start of picture text -----**<br>
3<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## About OHE 

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE, and our governance is the responsibility of the Board of Trustees. 

The Board of Trustees has three sub-committees with advisory roles: 

- Research Committee: Provides advice and guidance to OHE on its research programme 

- Policy Committee: Advises OHE on engaging with policymaking and meeting its Charitable Objects 

- Editorial Panel: Guarantees the quality of OHE’s publications. 

The Office of Health Economics wholly owns OHE Consulting Limited, which carries out consulting work for third parties. Its profits are gift-aided to OHE and fund our research and charitable activities. 

OHE is an Independent Research Organisation (IRO). This status was awarded in 2020 by UK Research and Innovation (UKRI) which – through the seven Research Councils, Innovate UK and Research England – allocates more than £8.8 billion in research funding, primarily from the Department for Science, Innovation, and Technology’s (DSIT) R&D budget. 

IRO status recognises the high quality of OHE’s independent research, on par with the UK’s higher education institutions, and makes us eligible to apply for UKRI funding on the same terms to better fulfil our charitable aims. 

## Priorities 

We emphasise projects that tackle impactful policy and strategic issues with current and future significance. Our work involves stakeholders, clients, and external experts to obtain crucial new policy insights and identify strategies and optimal choices. 

Although OHE is based in London, we undertake projects both in the UK and internationally. We work collaboratively with a wide network of academics and other partners worldwide. 


**----- Start of picture text -----**<br>
4<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


Snapshot of the year 

Our research and dissemination activity in 2025 reached further and covered more ground than ever before. 

We continued to work on a broad range of topic areas – from drug pricing reform to antimicrobial resistance – reaching a wide range of audiences around the world. 


**----- Start of picture text -----**<br>
5<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Snapshot of the year 

2025 was a year of growth across every part of our work. We published 43 research articles, 26 of them in external peer-reviewed journals, alongside 26 Insights and 22 Bulletins, and won 12 new research grants worth £1.12 million. 

Our team delivered 122 presentations at conferences and policy events in the UK and internationally, hosted the UK’s longest-running academic health economics conference in Brighton and drew over 325 registrations to the OHE Annual Lecture. 

Publication downloads rose 26% to 9,487, LinkedIn followers grew 30% to 16,512, and our fastest-growing audiences were in the Middle East and Asia-Pacific. The figures below set out the year at a glance. 



**----- Start of picture text -----**<br>
6<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


## Charitable activities & impact 

Each year we deliver on our Charitable Objects and maintain our social purpose, where the charitable objects are: 

- Promotion of evidence-based health care policy by carrying our research on the economics of health, health care systems, and the life sciences industry 

- Promotion of effective and efficient use of health care resources by advancing the use of economic approaches to support decisionmaking 

- Facilitating decision-making and awareness of health care policy issues by encouraging debate and disseminating relevant health economics research 


**----- Start of picture text -----**<br>
7<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 



**----- Start of picture text -----**<br>
8<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 



**----- Start of picture text -----**<br>
9<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 



**----- Start of picture text -----**<br>
10<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


## Strategic Research Themes 

In 2025, OHE’s research was organised across four interlinked themes that underpin our ambition to shape smarter policies, foster innovation, and improve health every day. 

- Our work in climate and health looks at the climate crisis as one of the most urgent health issues of our time. 

- • Our work in prevention addresses how to transition from a sickness-based model to one rooted in preventative health. 

- Our ongoing expertise in health technology assessment (HTA) considers how to balance cost with equitable access to inform robust, evidence-based decision making. 

- Our research in innovative pricing and drug development looks at balancing patient access with health-system sustainability, all while incentivising research and innovation into new, life-saving therapies. 


**----- Start of picture text -----**<br>
11<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT** 

## Climate & health 

We address the complex intersection of climate change and health through research, events, and policy work. In 2025 we started ECO-CHICA, a Wellcome Trust funded project with LSHTM valuing the health cobenefits of climate mitigation. We also awarded our Policy Innovation Prize for sustainable innovation, and examined how the NHS is performing against its sustainability goals. 

ohe.org ohe.org 

12 12 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Climate & health 

The climate crisis affects health in ways that are wide-ranging, unevenly distributed, and difficult to isolate. It poses deep challenges not only for service delivery but for how we define value, whose preferences we measure, and how we account for intergenerational and regional equity. Addressing the intersection of health and climate is therefore a cornerstone of OHE’s work, and in 2025 we began the year by awarding our Policy Innovation Prize jointly to two proposals for incentivising environmentally sustainable innovation in the life sciences, and went on to publish Insights, host events and start new research addressing this topic. 

Our largest project in this area is ECO-CHICA, a Wellcome Trust-funded collaboration with the London School of Hygiene & Tropical Medicine (GHECO and CCPH) and the EuroMediterranean Center on Climate Change (CMCC). The grant (£156,284, via LSHTM) was awarded in December 2024 and was live throughout 2025. The project develops methods to value the health co-benefits of climate change mitigation, contributing to OHE’s growing portfolio at the intersection of health and environmental economics. Early outputs included a published protocol for a literature review on guidance for the economic evaluation of the health impacts of climate action (Wellcome Open Research, 2025). 

On 8 July 2025 we hosted the webinar ‘Valuing health in an era of climate crisis: informing policy through economic evidence’, on the role of health economics in informing just, sustainable and evidence-based decision-making. We also examined how the NHS is performing against its sustainability goals, and our research portfolio grew to include work on the decarbonisation of health and social care under our Policy, Organisation and Incentives in Health Care Systems theme. 

In further outreach, OHE also presented on health, climate and sustainability at international conferences including the Global Sustainable Development Congress 2025 in Istanbul. 

Our Policy Innovation Prize, awarded on 24 January 2025 at its second award ceremony, distributed £40,000 to the winners, Professor Andrew Briggs and Professor Thomas Pogge, for proposals on how economic policies can incentivise environmentally sustainable innovation in the life sciences. 


**----- Start of picture text -----**<br>
13<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT** 

## Prevention 

We prioritised prevention in 2025 through our commentary on financing prevention in the NHS 10 Year Health Plan and our Annual Lecture delivered by Professor Anita Charlesworth. Our work on the socioeconomic value of adult immunisation and the business cost of respiratory infections continue to have an impact internationally. Key research findings included adult vaccines returning up to 19x their investment, cervical cancer's £406 million preventable UK burden, and respiratory infections costing £44 billion in productivity losses – all receiving significant media coverage. 

ohe.org ohe.org 

14 14 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Prevention 

With the UK Government’s NHS 10 Year Health Plan and this year’s Annual Lecture focused on prevention and related topics, OHE has contributed to national and global dialogue and debate on prevention and prioritised this line of research. 

On the NHS 10 Year Health Plan, we provided commentary and insight to major media outlets, including the Financial Times and the Guardian, before, during and after the UK Government published its plan, with a focus on financing prevention and on elevating health above short-term political cycles. Chief Executive Graham Cookson argued in the Financial Times for a new consensus on prevention, and OHE published two comment pieces in Public Sector Focus on prevention financing and the move towards a digitally enabled workforce. The 10 Year Plan was also the topic of our Annual Lecture, given by Professor Anita Charlesworth, and the subject of a series of Insights on our website. 

Our 2024 report on the socio-economic value of adult immunisation continued to have international impact in 2025 through media coverage (including CNN Greece, FORTUNE Italy, Health Service Journal and Healthcare Asia), a citation in a House of Lords briefing on incorporating societal and economic benefits in vaccine HTA, and invitations to high-level forums including the Global Vaccination Summit and a colloquium at the French Ministry of Health. Follow-on peer-reviewed articles on the broader socio-economic value of adult respiratory vaccination in the UK and Japan were published in Expert Review of Vaccines, and a ten-country cost-benefit analysis in Human Vaccines & Immunotherapeutics. 

Our research into the business cost of respiratory infections reached policymakers, industry and the public throughout 2025. This research was cited by columnist Polly Toynbee in the Guardian and in a letter to the Telegraph by Director Amanda Cole. The findings also informed an OHE submission to a parliamentary inquiry on the ageing workforce, and featured in CEO Graham Cookson’s panel discussion at Economist Impact’s Future of Health Summit. In addition, we developed an interactive tool that lets businesses estimate their own costs, which also received media coverage. The work supports the prevention agenda by showing that short-term respiratory infections are an underestimated drain on employees, businesses, and the economy. 

Our prevention research also shaped public debate on end-of-life and dementia care in 2025. Our work on unrelieved pain in palliative care featured in a BBC News segment ahead of the assisted dying debate, as well as on LBC Radio and in the Daily Mirror, and was cited by columnist Polly Toynbee in the Guardian. Separately, our research on dementia care was covered on BBC Radio 4 and BBC Radio Lancashire. 

Finally, Senior Principal Economist Simon Brassel wrote to the Guardian on expanding where vaccines are administered in response to rising measles cases. 


**----- Start of picture text -----**<br>
15<br>**----- End of picture text -----**<br>


ohe.org ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT** 

Health Technology Assessment 

We demonstrated HTA expertise in 2025 through peer-reviewed work on HTA reforms across agencies and early HTA, and our international "Around the World in HTAs" series, extended to Canada, Kenya and Argentina, was our most-read and highest-performing content of the year. Closer to home, OHE commentary on the NICE cost-effectiveness threshold informed the national conversation around the change. 

16 166 

ohe.org ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Health Technology Assessment 

OHE’s ongoing expertise in Health Technology Assessment (HTA) was reflected in 2025 in our publications and engagement: our highest-performing content on LinkedIn, our mostdownloaded reports and our most-read Insights were all in the area of understanding HTA practices globally, including how HTA agencies set standards and influence one another. 

Our peer-reviewed outputs this year included a comparative analysis of HTA reforms across agencies – processes, drivers and interdependencies (International Journal of Technology Assessment in Health Care, commissioned and funded by MSD), a consensus definition of early HTA developed with an HTAi working group, and work applying early HTA to inform investment in novel health technologies in the US. 

We continued our international outlook on HTA developments with our ‘Around the World in HTAs’ Insight series, extended in 2025 to cover Kenya, Canada and Argentina, with four more editions in the pipeline. This series was among OHE’s most-downloaded and most-read output and our highest-performing content on LinkedIn. 

Our Insights and publications continued to demonstrate our expertise on NICE decision making. OHE spokespeople were approached for comment on the review of the NICE costeffectiveness threshold, resulting in an interview in the Pharmaceutical Journal and an Insight on the threshold review. 

OHE spokespeople continued their thought leadership in this area, and on 28 January 2025 we hosted a roundtable with a Department for Business and Trade Andean Regulatory Mission on regulatory and HTA processes in England and the international influence of NICE. 

We also contributed to HTA capacity-building internationally through presentations at conferences including ISPOR Montreal and Arab Health Dubai, and through our BRAVER roadmap to broader assessment of the value of health interventions in the Asia-Pacific region, one of our most-downloaded reports of the year. 


**----- Start of picture text -----**<br>
17<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT** 

Innovative pricing & drug development 

In 2025, OHE shaped global debate on pharmaceutical pricing and access — most notably through high-profile analysis of the US 'Most Favoured Nation' proposals that reached policymakers and media in the UK and abroad, while publishing peer-reviewed research on combination therapy valuation, alternative payment models, biosimilars markets and biopharmaceutical investment, and contributing evidence to UK and Japanese parliamentary inquiries on medicine shortages. 

18 188 

ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Innovative pricing & drug development 

OHE has played an active role in shaping national and international debates on pharmaceutical policy, pricing, and access. In 2025 we responded to the US ‘Most Favoured Nation’ drug pricing proposals, focusing on the potential impact both in the US and internationally. Director Amanda Cole was interviewed in the British Medical Journal and POLITICO on the impact on industry and patient access in the UK, and Chief Executive Graham Cookson spoke to POLITICO on the policy’s effects on pricing abroad, in coverage syndicated widely, including on Oireachtas TV. OHE spokespeople were also frequently approached by reporters at The Times, the Financial Times and the Economist to provide context and information around the US–UK Pharmaceutical Agreement. 

US drug pricing reform was also the topic of Graham’s opening remarks at ISPOR Montreal, which was later cited in the Pink Sheet. Our analysis also reached audiences through Insights and social channels, with our Insight explaining the levers at play with US drug pricing being the second most read Insight of the year. 

OHE publications this year addressed critical challenges, including a general outcome-based value attribution framework for combination therapies (Value in Health), a framework for the effective implementation of alternative payment models for innovative medicines (Applied Health Economics and Health Policy), the price effects of biosimilars in the United States and a framework for sustainable global biosimilars markets, and an analysis of how the US Congressional Budget Office’s model of biopharmaceutical investment decision-making compares with investor insights (Health Affairs Scholar). 

OHE submitted written evidence to a UK Parliamentary inquiry on medicine shortages, drawing on previous research on drug shortages. We were also invited to present our findings on the global implications of drug shortages at a study session at the Japanese Diet. 

Our core-funded research under the Economics of Innovation theme examined biosimilar market dynamics, diversity of supply in rare-disease markets, pharmaceutical regulation after Brexit, and the commercial case for investment in ALS. 

OHE’s research and perspectives continued to reach broad audiences through media and stakeholder engagement, with our ‘Most Favoured Nation’ analysis in particular featuring in prominent UK and EU outlets, and a brown-bag seminar on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). 


**----- Start of picture text -----**<br>
19<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

Project spotlights 

Beyond our work in our three priority areas, there were a wide range of other impactful projects that saw great progress in 2025. Here are just a few more: 

- Around the World in HTAs 

- New HORIZON grants: TEN4CARE and PREDICT FTD 


**----- Start of picture text -----**<br>
20<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Project spotlights 

## **Around the World in HTAs** 

- Our flagship HTA Insight series was extended in 2025 to cover Kenya, Canada and Argentina, with four more editions in the pipeline. 

- The series explores how HTA agencies around the world set standards and influence one another, helping decision-makers understand global trends in HTA practice. 

   - It was among OHE’s most-downloaded and most-read output of the year and our highest-performing content on LinkedIn. 

   - It was complemented by peer-reviewed work including a comparative analysis of HTA reforms across agencies – processes, drivers and interdependencies (International Journal of Technology Assessment in Health Care, 2025). 

- OHE spokespeople were approached for comment on the change to the NICE costeffectiveness threshold, resulting in an interview in the Pharmaceutical Journal. 

Understanding HTA practices globally was OHE’s top-performing content area of 2025, with the Around the World in HTAs series driving our highest LinkedIn engagement, our most-downloaded reports and our most-read Insights. 

## **New HORIZON grants: TEN4CARE and PREDICT FTD** 

TEN4CARE is a HORIZON grant awarded in September 2025 (£306,544) on an injectable and implantable nanocomposite hydrogel for tendon and ligament repair. The award reflects the dividends from networks and relationships built through previous European projects. 

PREDICT FTD is a HORIZON grant awarded in January 2025 (£263,512) on the societal costs of frontotemporal dementia and the economic value of biomarker-led early diagnosis. Both projects sit within our Value, Affordability and Decision Making research theme. 


**----- Start of picture text -----**<br>
21<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


Our growing global footprint 

In 2025, OHE continued to deepen its international engagement, reflecting a strategic commitment to global collaboration and impact. 

Building on its longstanding reputation for thought leadership in health economics and policy, OHE extended its reach through international research partnerships, our Around the World in HTAs series and presentations at major international conferences including ISPOR Montreal, Arab Health Dubai and the Global Sustainable Development Congress in Istanbul. 

Our presence at international forums, participation in regional policy dialogues, and contributions to crossborder research projects have not only amplified our voice but also enriched our perspectives. 


**----- Start of picture text -----**<br>
22<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Our growing global footprint 

As we continue to grow our global network, this section highlights the milestones, collaborations, and regional focus areas that are shaping OHE’s internationalisation journey. From new strategic alliances to region-specific research priorities, we are proud to share how OHE is helping to shape health policy and economics on a truly global scale. 

The Middle East was our fastest-growing region in 2025. Graham Cookson spoke on two panels at Arab Health in Dubai, and Charlotte Ashton joined two panels at Abu Dhabi Global Health Week and met Bahrain’s Minister of Health. We began providing HTA advisory services to the Abu Dhabi Department of Health, and Martina Garau represented OHE at the HTAi and Tunisian Ministry of Health MENA regional meeting in Tunis. Our work was covered by the Bahrain News Gazette, the Bahrain News Agency, Al Ayam and Al Bilad. 

Elsewhere, we launched the BRAVER report with the ISPOR Singapore chapter in Asia and established a new Policy Horizons series in the US, jointly funded by GSK and Bristol Myers Squibb. This activity is reflected in our reach: LinkedIn followers grew by 575% in the Middle East, 91% in Asia-Pacific, 49% in Africa, 48% in South America, 29% in North America and 19% across the UK and Europe. OHE speakers appeared at events in the UK (29), Europe (18), North America (10), the Middle East (8), Asia-Pacific (6) and South America (2). 

## **2025 Global Partnerships** 











**----- Start of picture text -----**<br>
23<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


Our research outputs 

We present our publications in five main groups: 

- Publications in external peer-reviewed journals 

- • Publications on OHE’s website (peer-reviewed through the OHE reviewing process) 

- OHE reports 

- Books and chapters 

- Working papers in external institutions 

Our research activities resulted in 43 publications in 2025, alongside 26 Insights and 22 Bulletins. 


**----- Start of picture text -----**<br>
24<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Our research outputs 

OHE published 43 research articles in 2025: 26 in external peer-reviewed journals and 17 as OHE peer-reviewed publications. This compares with 22 and 14 respectively in 2024, increases of 18% and 21%. We also increased our output of Insights, Bulletins, and News Updates by 27% compared with 2024. We published 26 Insights (an 18% increase) and moved our Bulletin to twice monthly, raising the total from 16 in 2024 to 22 in 2025 (a 38% increase). Recent Insights addressed the government’s 10-year plan for the NHS, the review of the NICE cost-effectiveness threshold, and the expansion of the HTAs Around the World series to include Kenya, Canada, and Argentina. 

In the last five years, 62 OHE-authored peer-reviewed journal articles have now accrued 10 or more citations, 34 have 20 or more, eight have 50 or more and six have passed 100. The full breakdown by year of publication is given in _Appendix A_ , along with details of the ten most cited OHE journal articles since 2020. Some articles are published in highimpact journals and thus strengthen OHE’s reputation as an independent research organisation and ensure our work informs both academic and policy communities. 

Our OHE peer-reviewed publications serve our mission well to advance health economics and evidence-based policy. Covering themes from value assessment and HTA reform to biosimilars, vaccination, and health system resilience, these articles contribute to global debates and practical solutions for sustainable healthcare. 

Among these commissioned outputs, the ones with highest engagement included Averting the Trajectory of HIV in Europe (405 downloads), Taking STRIDES: The Value of Diagnostics Against AMR (282 downloads), and The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region (298 downloads). 

Core-funded research remained active, with 12 active projects. Several led to journal publications, including Navigating Change: A Comparative Analysis of Health Technology Assessment Reforms Across Agencies (IJTAHC, 2025) and Effect of Caregiver Burden on the Quality of Life of Informal Caregivers of People with Cystic Fibrosis in the United Kingdom (Quality of Life Research, 2025). Others progressed through data collection and manuscript drafting, with further submissions expected in early 2026. 

A full list of the ongoing core-funded projects, arranged by Research Theme, can be found in _Appendix B_ . Overall, our core-funded pipeline reflects our commitment to support work that is relevant for both health economic methods and health policy. 


**----- Start of picture text -----**<br>
25<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


## Engagement & dissemination 

OHE delivered a broad programme of educational activities in 2025 across virtual, in-person and hybrid formats, including specialised webinars, workshops, the second Innovation Policy Prize award and our Annual Lecture. 

OHE also organised and hosted the Summer 2025 meeting of the Health Economics Study Group (HESG) in Brighton, the UK’s longest-running academic health economics conference, bringing together around 200 participants. This section provides an update on all the OHE events held over 2025. 


**----- Start of picture text -----**<br>
26<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Engagement & dissemination 

## **Webinars** 

- On 8 January 2025, OHE streamed the 2024 Insights and Reflections webinar live to 222 registrants. The webinar explored which OHE research trends had the biggest impact in the previous year, covering drug shortages, vaccines, environmental sustainability and global policy shifts. 

- On 10 June 2025, OHE held a PGx-CERSI webinar on methodological developments in the health economic assessment of pharmacogenomics from NHS and societal perspectives. 

- On 8 July 2025, OHE led a webinar titled ‘Valuing health in an era of climate crisis: informing policy through economic evidence’, on the role of health economics in just, sustainable and evidence-based decision-making. 

## **Roundtables** 

- On 28 January 2025, OHE hosted a roundtable with a Department for Business and Trade Andean Regulatory Mission on regulatory and HTA processes in England and the international influence of NICE. 

- On 4 December 2025, OHE held a roundtable for the Change Initiative Prevention Financing programme on impact, dissemination routes, stakeholder engagement and new areas of collaboration. 

## **OHE external events** 

- On 24 January 2025, OHE held the second Innovation Policy Prize Award Ceremony, distributing £40,000 to the winners, Professor Andrew Briggs and Professor Thomas Pogge, for proposals on how economic policies can incentivise environmentally sustainable innovation in the life sciences. 

- In summer 2025, OHE organised and hosted the Summer 2025 meeting of the Health Economics Study Group (HESG) in Brighton, the UK’s longest-running academic health economics conference, which brought together around 200 participants for three days of presentations and methodological debate. 

- 2025 Annual Lecture: On 30 September 2025, at the Royal College of Physicians, Professor Anita Charlesworth MBE gave the OHE Annual Lecture on the NHS’s new strategy, the 10 Year Health Plan. The lecture received over 325 registrations. 

- OHE also took part in international forums during the year, including the Global Vaccination Summit and a colloquium at the French Ministry of Health on the socioeconomic value of adult immunisation, and the Global Sustainable Development Congress in Istanbul. 

## **Brown-bag lunch seminars** 

Finally, we also hosted four different brown-bag lunch seminars: 

- The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) – Phill O’Neill 


**----- Start of picture text -----**<br>
27<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

- A comparative analysis of FDA and EMA approvals of rare disease therapies – Jay Sedam (summer placement student) 

- Practical techniques for using Canva – Julia Toth 

- A systematic review of generic preference-based measures of health in the context of climate change – Enobong Umoh (MSc placement student) 

## **Website, Insights & social media** 

Activity on our website and social media channels grew steadily throughout 2025. We launched a newly redesigned website with improved navigation, search, and search-engine performance. Publication downloads rose 26% to 9,487 (from 7,529 in 2024) and total website visits grew 6% to 122,021 (from 115,220). Our mailing list grew 7% to 12,171 subscribers; total unique opens rose 62% to 43,987 and unique clicks rose from 2,689 to 4,474, while the email bounce rate fell by 33% (from 207 to 139). 

On LinkedIn we grew 30%, gaining 3,763 new followers (compared with 2,823 in 2024) to more than 16,512 by year end, and introduced the ‘In Focus’ series highlighting key publications. Our X (Twitter) following was broadly stable at 5,872 (up 0.5%), reflecting reduced activity on the platform. 

## **External presentations** 

The 122 presentations delivered in 2025 were given by 33 OHE team members at conferences, webinars, workshops and policy events in the UK and internationally. Topics spanned health economics methods, HTA, rare diseases, vaccination and antimicrobial resistance, workforce and system performance, environmental sustainability, and the economic evaluation of climate and public health interventions, with audiences ranging from small academic sessions to large international conferences including ISPOR Montreal, Arab Health Dubai, and the Global Sustainable Development Congress in Istanbul. The full list can be found in _Appendix C_ . 

## **Advisory Roles** 

The number of advisory roles held by OHE staff members has continued to grow, reflecting their strong influence on policy and their recognised contributions to the research and policy community. This impact aligns with OHE’s charitable objective of steering health policy and decision-making in health economics and building capability by transferring health economics research skills to students and other individuals at different stages of their careers. A full list of OHE staff memberships of advisory panels, boards and committees is given in _Appendix D_ . 


**----- Start of picture text -----**<br>
28<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


## Financial Review 

In 2025, OHE remained an organisation undertaking research and related activities according to its charitable objects and status of independent research organisation. OHE owns the sole share in OHE Consulting Limited with the purpose of enabling OHE to: 

- employ a larger staff team than would be possible using research income alone 

- allow staff to gain knowledge, skills and experience undertaking consulting projects that can be carried across into research and research-related projects 

- most importantly, invest the profits generated from consultancy work as Gift Aided to OHE, to fund OHE's activities in 2025. 


**----- Start of picture text -----**<br>
29<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Financial Review 

## **Financial Performance in 2025** 

The financial statements of OHE comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts following The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) (“Charities SORP FRS 102“). 

OHE’s consolidated turnover (OHE and OHE Consulting Limited) in 2025 was **£5.69m** , compared with £5.24m in 2024. Expenditure totalled **£5.23m** , leaving a net income of £457k. Of the estimated expenditure, staff costs in 2025 amounted to approximately **£3.57m** , or around 68% of the total. 

The consolidated accounts for OHE are included as an Annex to this report. 

## **Sources of Funding** 

The sources of funding for OHE are summarised below. The financial reports attached provide more details about OHE income and expenditure. 

The estimated consolidated income of **£5.69m** comprises: 

|The estimated consolidated income of**£5.69m**comprises:||
|---|---|
||£000|
|Donations – research grants|302|
|Income from charitable (research) activities*|948|
|Interest|23|
|Total research income|1,274|
|OHE Consulting Income|4,415|
|Total Income|5,688|
|Donations are from the ABPI and are for two distinct purposes:||
||£000|
|Support for core research activities|100|
|Grant towards fnancing of support activities|396|
|Total|496|



*Income from charitable (research) activities came from several sources. Major research projects and funders included: HORIZON European Commission Grants (including TEN4CARE and PREDICT FTD), Wellcome Trust (ECO-CHICA), the Change Initiative, EuroQol Research Foundation and Parkinson’s UK. 

## **Reserves and going concern** 

Revenue has grown consistently over the decade since OHE became a charity, with a single loss (2023). At 31 December 2024, reserves were £1.57m. Given the estimated 2025 surplus, reserves are expected to exceed £2m, estimated at around £2.3m, equivalent to roughly 44% of forecast 2026 expenditure or 56% of staff costs. 

A consistent record of revenue growth, predictable surpluses, and significant reserves indicates that OHE is a stable and sustainable charity and can be regarded as a going concern. OHE’s reserves policy is to hold three to six months of payroll costs as cash reserves; as a large charity, OHE will review this policy at the March 2026 Board meeting and has requested a written going-concern assessment from its auditors ahead of the June 2026 Board meeting. 


**----- Start of picture text -----**<br>
30<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


## Grants & Contract Research 

The number and amount of research grant funded projects in 2025 amounts to £3.87 million, 49% higher than at the end of 2024 (£2.6 million). 

The pipeline and the research grant applications show that 2025 was a record year for OHE research grant income. New research grants awarded in 2025 amount to £1.12 million (up 19%), the value of lost applications fell 45%, and networks built through previous European HORIZON projects continued to pay dividends, including the TEN4CARE grant. 

Contract research also had a strong year, with 84 new contracts won in 2025 worth a combined £5.22 million and a year-end pipeline of 51 opportunities valued at £7.07 million (£3.95 million on a probability-adjusted basis). 


**----- Start of picture text -----**<br>
31<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Grants & Contract Research 

## **2025 Research Grants Activity** 

## **Key takeaways:** 

- 2025 was a record year for OHE research grant income, with increases on 2024 across every metric. 

- The value of live grant-funded research projects at the end of 2025 was £3.87 million, 49% higher than at the end of 2024 (£2.6 million). 

- The total value of new research grants awarded in 2025 was £1.12 million, 19% higher than in 2024 (£0.94 million), across 12 new grants. 

- Networks built through previous European projects continued to pay dividends: in 2025 we secured the TEN4CARE HORIZON grant and submitted further applications. 

- The value of lost applications fell 45% on 2024 (from £4.4 million to £2.55 million), reflecting a more selective application strategy. 

Government and other grant income received in 2025 is reported to the Charity Commission through the annual return. OHE’s research grant activity strengthened markedly during the year. The value of live grant-funded research projects at the end of 2025 was £3.87m, 49% higher than at the end of 2024 (£2.6m). The total value of new research grants awarded in 2025 was £1.12m, 19% higher than in 2024 (£0.94m). Networks built through previous European projects continued to pay dividends: in 2025 we secured a further HORIZON grant (TEN4CARE) and submitted further applications. Our contract research portfolio also grew, with new live contracts worth £5.0m by year end (94% higher than £2.6m in 2024) and a pipeline worth £3.9m (£2.2m in 2024). 

As of December 2025, OHE held 12 new grants won in 2025 with a combined budget of £1.1m, 14 ongoing projects from previous years totalling £1.74m, and projects closed during 2025 worth £1m, giving a combined live portfolio of £3.87m. Projects are classified under the four research themes: Value, Affordability and Decision Making (VADM); Policy, Organisation and Incentives in Health Care Systems (POIHS); Economics of Innovation (EoI); and Measuring and Valuing Outcomes (MVO). 

## **PROJECTS WON IN 2025** 

The new projects won during 2025 were funded by bodies including the European Commission, Innovate UK, Nesta, the EuroQol Research Foundation, the National Institutes of Health, the CML Advocates Network and the Universities of Sussex and Manchester. The full list, with project title, theme, year won and budget, is given in _Appendix E_ . 

## **PROJECTS WON PRIOR TO 2025 AND STILL LIVE** 

Thirteen projects won in earlier years remained live during 2025, funded by bodies including the European Commission, the CML and Acute Leukaemia Advocates Networks, the London School of Hygiene & Tropical Medicine, the EuroQol Research Foundation and High Flow Therapy UK. The full list, with project title, theme, year won and budget, is given in _Appendix E_ . 


**----- Start of picture text -----**<br>
32<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## **PROJECTS WON PRIOR TO 2025 AND CLOSED IN 2025** 

Seven projects won in earlier years were completed and closed during 2025, including work for IFPMA, the Health Foundation, Amicus Therapeutics, Curta, Parkinson’s UK and UCL. The full list, with project title, theme, year won and budget, is given in _Appendix E_ . 

## **PROJECTS IN THE PIPELINE (AS OF DECEMBER 2025)** 

OHE’s grant pipeline remains strong. The table below lists proposals under consideration with their nominal value, the assessed probability of success, and the probability-adjusted value. The DG SANTE framework bid has no budget, being an accreditation that allows OHE to bid for European Commission DG SANTE projects in consortium. 

Twenty-four proposals remained under consideration at the year end, led by submissions to the European Commission, the NIHR, the Fleming Initiative, Queen Mary University of London, the Acute Leukaemia Advocates Network, the EuroQol Research Foundation and Verian. Nominal and probability-adjusted values for each proposal are given in _Appendix E_ . 

Projects shown at £0 were still being costed at year end. Adjusted values apply the probability of success to the nominal budget. 

## **PROJECTS SUBMITTED AND LOST IN 2025** 

In 2025, 12 grant proposals were unsuccessful, with a combined value of £2.5m, many of them large, multi-partner applications under Wellcome Trust, NIHR, and Horizon Europe calls. The value of lost applications fell 45% on 2024 (from £4.4m to £2.55m), reflecting a more selective application strategy. 

Twelve proposals submitted during 2025 were unsuccessful, including bids to the NIHR, the Wellcome Trust, Science for Africa, UKRI, the Physicians Committee for Responsible Medicine, the EuroQol Research Foundation and Astellas Pharma US. The full list, with project title, theme and value, is given in _Appendix E_ . 

## **Contract research projects** 

Contract research is carried out by OHE Consulting Limited, the charity’s wholly owned subsidiary. In 2025 the subsidiary generated income of £4.42m, equivalent to 78% of OHE’s consolidated turnover of £5.69m, making it the largest single source of funds supporting the charity’s work. Its taxable profits are gift-aided in full to OHE, where they fund the independent research programme alongside grant income and donations from the ABPI. 

Across the portfolio, contract research remained concentrated in Value, Affordability and Decision Making, which accounted for the majority of the value delivered during the year. Work under Economics of Innovation was generally smaller in scale, shorter in duration and more often dissemination-focused, while Policy, Organisation and Incentives in Health Care Systems and Measuring and Valuing Outcomes projects were fewer in number but typically of moderate value. The shape of the portfolio was barbelled, combining a small number of large multi-year studies with a long tail of short, low-value commissions. The pipeline at the year end points towards a shift, with health systems and policy work accounting for a larger share of expected value than in the delivered portfolio. 

Project-level detail is not reported here. Individual contracts are commercially sensitive, and the work is undertaken by the trading subsidiary rather than as a charitable activity of OHE itself. 


**----- Start of picture text -----**<br>
33<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 


Structure, Governance & Management 


**----- Start of picture text -----**<br>
34<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Structure, Governance & Management 

This is OHE’s ninth annual submission to the Charity Commission for England and Wales since registration as a charity in December 2016. The Board of Trustees sits at the top of OHE’s governance structure, supported by the Research Committee, the Policy Committee, and the Editorial Panel. The Research Committee guides OHE on research methods, oversees the core research grant programme, and assures the quality and independence of OHE’s research. The Policy Committee advises on policy impact and engagement, and the Editorial Panel guarantees the quality of OHE’s publications. 

## **Trustee news in 2025** 

It is with great sadness that OHE records the death of Trustee and long-standing ABPI colleague Paul Catchpole during 2025. His contribution to OHE, the ABPI, and the wider healthcare sector was substantial and widely recognised. The ABPI appointed Victoria Jordon, Director of Value and Access at the ABPI, as his successor; she joined the Board at the December 2025 meeting. 

## **Trustees** 

Anita Charlesworth, The Health Foundation (Chair) Richard Torbett, ABPI Werner Brouwer, ESHPM (appointed 31 March 2022) Patrick Holmes, Pfizer (appointed 31 January 2022) Thomas Allvin, EFPIA (appointed 23 February 2023) Victoria Jordon, ABPI (appointed December 2025) 

Changes during the year: Paul Catchpole, ABPI (appointed 4 October 2023; died 2025); Margaret Kyle, Mines ParisTech (OHE) (resigned 31 December 2024) 

## **Senior Management** 

**Chief Executive Officer** Prof Graham Cookson 

**Deputy Chief Executive Officer** Prof Lotte Steuten **Chief Research Officer and Head of Education** Prof Mireia Jofre-Bonet 

**Directors** Charlotte Ashton Martina Garau Chris Skedgel Tim Watson **Associate Directors** Amanda Cole Grace Hampson 

**Registered Office:** 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB Charity number: 1170829; Company number: 09848965 

**Auditor:** BDO LLP , Statutory Auditor & Chartered Accountants, 2 City Place, Beehive Ring Road, Gatwick, West Sussex RH6 0PA. **Bankers:** National Westminster Bank Plc, PO Box 113, Cavell House, 2A Charing Cross Road, London 


**----- Start of picture text -----**<br>
35<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **CONTRACT RESEARCH ANNUAL CHARITY REPORT** 

## Appendices 


36 65 

ohe.org ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Appendix A — Publications 

## **External peer-reviewed journal articles** 

_For external peer-reviewed journal articles, we provide information on the sources of financial support, number of citations, SJR indicator and ABS journal ranking._ 

|**JOURNAL REFERENCE**|**SOURCE OF**|**CITATIONS**|**SJR**|**ABS**|
|---|---|---|---|---|
||**FINANCIAL**||**(2024)**|**(2024)**|
||**SUPPORT**||||
|Hitch J, Denee T, Brassel S, Lee J, Michaelides M, Petersen J,|Contract|1|1.856|N/A|
|Alulis S, Steuten L. (2025) Challenges in Value Assessment|research||||
|for One-Time Gene Therapies for Inherited Retinal|(Johnson &||||
|Diseases: Are We Turning a Blind Eye? Value in Health.|Johnson)||||
|Jan;28(1):116-124.|||||
|https://doi.org/10.1016/j.jval.2024.08.009.Epub 2024 Oct|||||
|8. PMID: 39384069.|||||
|Steuten, L., Lothgren, M., Bruce, A., Campioni, M., & Towse, A.|Contract|6|1.856|N/A|
|(2025). Proposal for a General Outcome-Based Value|research||||
|Attribution Framework for Combination Therapies. Value in|(Amgen)||||
|health: the journal of the International Society for|||||
|Pharmacoeconomics and Outcomes Research, 28(1), 81–|||||
|87.https://doi.org/10.1016/j.jval.2024.07.019|||||
|Buiteman–Kruizinga, L. A., Meenen, D. M. P. v., Neto, A. S.,|Unfunded|15|2.751|N/A|
|Mazzinari, G., Bos, L. D. J., Heiden, P. L. J. v. d., … & Schultz, M.|||||
|J. (2025). Association of ventilation volumes, pressures and|||||
|rates with the mechanical power of ventilation in patients|||||
|without acute respiratory distress syndrome: exploring the|||||
|impact of rate reduction. Anaesthesia, 80(5), 533-542.|||||
|https://doi.org/10.1111/anae.16537|||||
|Henderson RH, Sampson C, Pouwels XGLV, Harvard S,|Unfunded|3|1.856|N/A|
|Handels R, Feenstra T, Bhandari R, Sepassi A, Arnold R.|||||
|(2025) Mapping the Landscape of Open Source Health|||||
|Economic Models: A Systematic Database Review and|||||
|Analysis: An ISPOR Special Interest Group Report. Value in|||||
|Health.  Feb 12:S1098-3015(25)00060-9.|||||
|https://doi.org/10.1016/j.jval.2025.01.019. Epub ahead of|||||
|print. PMID: 39952464.|||||
|Roth, J.A., Dayer, V.W., Jofre-Bonet, M. et al. (2025) Defning|Core funded|2|2.290|N/A|
|a Framework for Sustainable Global Biosimilars Markets|research||||
|Using Findings from a Targeted Literature Review. BioDrugs.|||||
|https://doi.org/10.1007/s40259-025-00710-8|||||
|Pinto, C., Norton, S., Cubi-Molla, P., Hurt, C., Chowdhury, S.,|Grant funded|0|1.356|N/A|
|Dooley, N., … Bogosian, A. (2025). Evaluating a digital mental|research||||
|health intervention for people with Parkinson’s (PACT):|[Parkinson’s UK||||
|acceptability and feasibility randomised controlled trial.|under Grant ref:||||
|Aging & Mental Health, 1–9.|H-2102; PI was||||
|https://doi.org/10.1080/13607863.2025.2478508|City St||||
||George’s,||||
||University of||||
||London]||||




**----- Start of picture text -----**<br>
37<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**JOURNAL REFERENCE**|**SOURCE OF**|**CITATIONS**|**SJR**|**ABS**|
|---|---|---|---|---|
||**FINANCIAL**||**(2024)**|**(2024)**|
||**SUPPORT**||||
|Hussain H, Keetharuth A, Wailoo A, Rowen D. (2025)|EEPRU via|0|3.600|N/A|
|Enhancing HRQoL assessment for economic evaluation in|University of||||
|dementia populations. Alzheimer’s Dement; 11:e70061.|Shefeld||||
|https://doi.org/10.1002/trc2.70061|||||
|Kumar G, Radu P, Cubi-Molla P, et al. (2025) Navigating|Contract|2|0.846|N/A|
|change: a comparative analysis of health technology|research (MSD)||||
|assessment reforms across agencies – processes, drivers,|||||
|and interdependencies. International Journal of Technology|||||
|Assessment in Health Care; 41(1):e21.|||||
|https://doi.org/10.1017/S0266462325000133|||||
|Pinto, C., Brown, J., Hurt, C. ...Jofre-Bonet, M. et al. (2025)|Grant funded|0|0.672|N/A|
|Acceptability and feasibility randomised controlled trial of a|research||||
|digital mental health intervention for people with|[Parkinson’s UK,||||
|Parkinson’s (PACT): trial protocol. Pilot Feasibility Stud 11,|PI was City St||||
|32.https://doi.org/10.1186/s40814-025-01594-9|George’s,||||
||University of||||
||London]||||
|McElwee, F., Cole, A., Kaliappan, G. et al. (2025) Alternative|Contract|3|1.291|N/A|
|Payment Models for Innovative Medicines: A Framework for|research||||
|Efective Implementation. Appl Health Econ Health Policy.|(Roche)||||
|https://doi.org/10.1007/s40258-025-00960-1|||||
|Jofre-Bonet, M., Roig, M.R. & Serra-Sastre, V. (2025)|No|0|0.760|2|
|Intimate partner violence and children’s cognitive|||||
|development. Empir Econ.https://doi.org/10.1007/s00181-|||||
|025-02746-9|||||
|Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD.|TBC|6|1.856|N/A|
|(2025) The Price Efects of Biosimilars in the United States.|||||
|Value in Health.  May;28(5):742-750.|||||
|https://doi.org/10.1016/j.jval.2025.02.008.Epub 2025 Mar|||||
|4. PMID: 40049325.|||||
|Grutters JPC, Bouttell J, Abrishami P, Ahmed SYM, Cole A,|No Funding|13|0.846|N/A|
|Dawoud D, Fernández-Barceló C, Frederix GWJ, Hawkins N,|||||
|Karnon J, Leadbitter S, McCabe C, Mueller J, Achiaw SO,|||||
|Partington A, Sampietro-Colom L, Seyahian A, Sucu R, Tew|||||
|M, van Katwyk S, Verboven Y, Wang Y; (2025) A Working|||||
|Group of HTAi. Defning early health technology|||||
|assessment: building consensus using Delphi technique. Int|||||
|J Technol Assess Health Care. Jun 2;41(1):e34.|||||
|https://doi.org/10.1017/S0266462325100123. PMID:|||||
|40452233; PMCID: PMC12178750.|||||
|Chowdhury, S., Cubi-Molla, P. & Mott, D. (2025) Efect of|Core funded|0|1.436|N/A|
|caregiver burden on the quality of life of informal caregivers|research||||
|of people with cystic fbrosis in the United Kingdom: a|||||
|cross-sectional study. Qual Life Res.|||||
|https://doi.org/10.1007/s11136-025-04021-x|||||
|Theakston, C., Napier, M., Brassel, S., Kamei, K., Ito, S., Vietri,|Contract|1|1.255|N/A|
|J., … Steuten, L. (2025). A beneft-cost analysis quantifying<br>the broader socioeconomic value of adult respiratory|research<br>(Pfzer)||||
|vaccination programs in Japan. Expert Review of Vaccines,|||||
|24(1), 633–643.|||||
|https://doi.org/10.1080/14760584.2025.2536092|||||




**----- Start of picture text -----**<br>
38<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**JOURNAL REFERENCE**|**SOURCE OF**|**CITATIONS**|**SJR**|**ABS**|
|---|---|---|---|---|
||**FINANCIAL**||**(2024)**|**(2024)**|
||**SUPPORT**||||
|Harrison, C., Brassel, S., Chowdhury, S., Theakston, C., Napier,|Contract||||
|M., Vietri, J., Steuten, L. (2025). The broader socio-economic|research||||
|value of adult respiratory disease vaccinations in the UK –<br>results from a beneft cost analysis. Expert Review of|(Pfzer)||||
|Vaccines, 24(1), 644–655.|||||
|https://doi.org/10.1080/14760584.2025.2536093|||||
|Cubi-Molla P, MacClancy C, Oyalo P et al. (2025) Guidance|Grant Funded|2|0.693|N/A|
|on the economic evaluation of the health impacts of|research||||
|climate action: a literature review protocol. [version 1; peer|Wellcome Trust||||
|review: awaiting peer review]. Wellcome Open Res, 10:354|contracting||||
|(https://doi.org/10.12688/wellcomeopenres.24029.1)|from LSTHM||||
|McGuire A, Wharton G, Hodgson S, Kourouklis D, Jofre-|Core funded|1|1.026|N/A|
|Bonet M, Tran DL, (2025). Health system sustainability and|research||||
|resilience: a preliminary provision of measurement through|||||
|a “mash-up” index. Health Economics, Policy and Law., pp.1–|||||
|13. DOI:https://doi.org/10.1017/S1744133125100182.|||||
|Hussain, H. et al. (2025) Mapping EQ-5D-5L Utilities in|EEPRU via|0|1.856|N/A|
|Dementia: Integrating Self and Proxy Reports. Value in|University of||||
|Health, Volume 28, Issue 8, 1204 - 1212|Shefeld||||
|Elsisi Z, Canestaro W, Steuten L, Hansen R. (2025) Applying|Core funded|0|0.846|N/A|
|early health technology assessment (e-HTA) to inform|research||||
|investment in novel health technologies in the US.|||||
|International Journal of Technology Assessment in Health|||||
|Care. 2025;41(1):e45.|||||
|https://doi.org/10.1017/S0266462325100275|||||
|Patel, A., Jofre-Bonet, M.,Hauck, K., Miraldo, M., Mistry, H.,|||||
|Premji, S.  (2025). Broadening the lens: a commentary on|||||
|Sheard and Cauana-Finkel’s account of women’s progress in|||||
|UK academic health economics. Social Science & Medicine,|||||
|Volume 382,2025,118411|||||
|https://doi.org/10.1016/j.socscimed.2025.118411|||||
|Hitch, J., Kumar, G., Schneider, P. et al. (2025) The Infuence|EuroQol|0|1.880|2|
|of Perspective on the Valuation of the EQ-5D-Y-3L: A|Foundation||||
|Comparison Using the OPUF Tool and a Discrete Choice|||||
|Experiment. PharmacoEconomics. https://d|||||
|oi.org/10.1007/s40273-025-01545-5|||||
|Matthias P Hofer, Priscila Radu, Mikel Berdud, Amanda Cole,|PhRMA|0|N/A|N/A|
|Graham Cookson, (2025) Understanding|||||
|biopharmaceutical investment decision-making: how does|||||
|Congressional Budget Ofce’s model compare to investor<br>insights?, Health Afairs Scholar, Volume 3, Issue 11,|||||
|November, qxaf200,|||||
|https://doi.org/10.1093/haschl/qxaf200|||||
|Miller, C.B., Bradley, D., Hall, S., Hayes, H., Chowdhury, S. and|Big Health Inc.|0|0.897|N/A|
|Sampson, C., (2025). Cost Savings Associated With Fully|||||
|Automated Digital Cognitive Behavioral Therapy for|||||
|Insomnia Disorder (SleepioRx): A Matched Control Study of|||||
|US Patients. Journal of Health Economics and Outcomes|||||
|Research, 12(2), pp.193–199.|||||
|https://doi.org/10.36469/001c.146434.|||||




**----- Start of picture text -----**<br>
39<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**JOURNAL REFERENCE**|**SOURCE OF**|**CITATIONS**|**SJR**|**ABS**|
|---|---|---|---|---|
||**FINANCIAL**||**(2024)**|**(2024)**|
||**SUPPORT**||||
|Hughes DA, Fong H, Hampson G, Plumpton CO, Sampson C.|Grant funded|0|1.155|N/A|
|(2025) Health economic considerations for|research||||
|pharmacogenomic services in the United Kingdom: The|||||
|Centre for Excellence in Regulatory Science and Innovation|||||
|in Pharmacogenomics. Br J Clin Pharmacol. 2025; 1-3.|||||
|https://doi.org/10.1002/bcp.70412|||||
|Chowdhury S, Brassel S, El Banhawi H, Bell E, Neri M,|IFPMA||||
|Steuten L. (2025) A cost-beneft analysis of adult|||||
|immunization programs across ten countries: Modeling the|||||
|socioeconomic value of immunization for older populations|||||
|compared to no vaccination. Hum Vaccin Immunother.|||||
|Dec;21(1):2602976.|||||
|https://doi.org/10.1080/21645515.2025.2602976.Epub|||||
|2025 Dec 18. PMID: 41410417; PMCID: PMC12716055.|||||



_Citations from Google Scholar as of January 2026. SJR is the SCImago Journal Rank indicator (latest year 2024). ABS is the Chartered Association of Business Schools journal ranking (4* highest to 1; latest 2024). N/A indicates no ranking available. Chartered Association of Business Schools (‘ABS’), UK: journal rankings go from 4* (highest) to 1 lowest)._ 

**Summary of citations over time, 2020–2025** 

|**NUMBER OF**|2020|2021|2022|2023|2024|2025|Total|
|---|---|---|---|---|---|---|---|
|**CITATIONS**||||||||
|**10+**|10|18|19|10|3|2|62|
|**20+**|8|11|11|2|2|0|34|
|**50+**|3|2|3|0|0|0|8|
|**100+**|3|0|3|0|0|0|6|




**----- Start of picture text -----**<br>
40<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## **Top 10 most cited publications since 2020** 

**1. 2,256 Citations** 

Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. _European Journal of Health Economics_ . (Epub ahead of print). DOI: 10.1007/s10198-021-01426-6. 

## **2. 404 Citations** 

Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. _Nature Medicine._ DOI: 10.1038/s41591-022-01717-2 

## **3. 214 Citations** 

Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. _Value in Health,_ Feb;23(2):139-150. doi: 10.1016/j.jval.2020.01.001. PubMed PMID: 32113617. 

## **4. 129 Citations** 

Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD, Steuten L, Fenwick E. (2020) Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. _Value in Health_ . Mar;23(3):277286. doi:10.1016/j.jval.2020.01.004. PubMed PMID: 32197720. 

**5. 112 Citations** 

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M., 2019. Comparing access to orphan medicinal products in Europe. Orphanet Journal of Rare Diseases, 14(1), p.95. 10.1186/s13023-019-1078-5. 

## **6. 104 Citations** 

Berdud M, Drummond M, and Towse A. (2020).  Establishing a reasonable price for an orphan drug. Cost Effectiveness and Resource Allocation https://doi.org/10.1186/s12962-020-00223-x 

## **7. 96 Citations** 

Steuten, L., Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. _Journal of Clinical Oncology_ , (3), pp. 1-10. DOI: 10.1200/CCI.19.00002. 

## **8. 93 Citations** 

Sampson, C.J., Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? PharmacoEconomics. DOI: 10.1007/s40273-019-00819-z. 

## **9. 88 Citations** 

Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., MestreFerrandiz, J., Oortwijn, W. and Oosterwijk, C., Tunis, S., Zamora, B. 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics, pp.1-8. 

## **10. 69 Citations** 

Mott DJ, Shah KK, Ramos-Goñi JM, Devlin NJ, Rivero-Arias O. (2021) Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? Medical Decision Making. DOI:10.1177/0272989X21999607 


**----- Start of picture text -----**<br>
41<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## **OHE peer-reviewed publications, funding, and number of downloads** 

|**PUBLICATION**<br>ALTERING THE TRAJECTORY OF HIV IN EUROPE<br>https://www.ohe.org/publications/altering-the-trajectory-of-hiv-in-europe/<br>THE BRAVER ROADMAP TO BROADER ASSESSMENT OF THE VALUE OF<br>HEALTH INTERVENTIONS IN THE ASIA-PACIFIC REGION<br>https://www.ohe.org/publications/the-braver-roadmap-to-broader-assessment-<br>of-the-value-of-health-interventions-in-the-asia-pacifc-region/<br>UNDERSTANDING THE FULL VALUE OF LONG-ACTING THERAPIES: LESS IS<br>MORE? https://www.ohe.org/publications/understanding-the-full-value-of-long-<br>acting-therapies-less-is-more/<br>TAKING STRIDES: THE VALUE OF DIAGNOSTICS AGAINST AMR<br>https://www.ohe.org/publications/taking-strides-the-value-of-diagnostics-<br>against-amr/<br>ANALYSING GLOBAL IMMUNISATION EXPENDITURE<br>https://www.ohe.org/publications/analysing-global-immunisation-expenditure/<br>THE VALUE OF CELL AND GENE THERAPIES TO THE UK ECONOMY<br>https://www.ohe.org/publications/value-of-cell-and-gene-therapies-to-the-uk-<br>economy/<br>CHALLENGES AND SOLUTIONS FOR BUDGET IMPACT ANALYSIS OF GENE<br>THERAPIEShttps://www.ohe.org/publications/challenges-and-solutions-for-<br>budget-impact-analysis-of-gene-therapies/<br>AN ANALYSIS OF NICE’S OPTIMISED DECISIONS FROM 2015 TO 2024<br>https://www.ohe.org/publications/an-analysis-of-nices-optimised-decisions-from-|**SOURCES OF**<br>**FINANCIAL SUPPORT**<br>**NUMBER OF**<br>**DOWNLOADS**|
|---|---|
||Contract research (ViiV<br>Healthcare)<br>405|
||Contract research<br>(Roche, MSD, Johnson &<br>Johnson)<br>298|
||Contract research (GSK) 285|
||Contract research<br>(bioMérieux)<br>282|
||Contract research<br>(Pfzer)<br>150|
||Contract research (Cell<br>and Gene Therapy<br>Catapult)<br>132|
||Contract research<br>(Johnson & Johnson<br>Innovative Medicines)<br>118|
||Contract research (ABPI) 92|
||Contract research<br>(Amicus Therapeutics<br>UK)<br>91|
||Contract research (MSD,<br>AstraZeneca, GSK)<br>78|
||Grant-funded research<br>(Challenge Works,<br>Longitude Prize on ALS)<br>70|




**----- Start of picture text -----**<br>
42<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Appendix B— Core-funded projects: 

## **Economics of Innovation** 

**PROJECT INVESTIGATORS UPDATE ON PROGRESS** Pharmaceutical policy and access Matthias Hofer, Phill O’Neill, Updates the first analysis of MHRA regulatory activity since 2021. to innovation in the UK after Brexit Mireia Jofre-Bonet Analysis of regulatory performance finalised with the help of an LSE MSc student and ready for dissemination in 2026; analysis of access to be progressed in 2026. 

## **Value, Affordability and Decision Making** 

|**Value, Afordability and**|**Decision Making**||
|---|---|---|
|**PROJECT**|**INVESTIGATORS**|**UPDATE ON PROGRESS**|
|Defning Afordability|Gayathri Kumar, Patricia<br>Cubi-Molla, Martina Garau,<br>Matthew Napier, Phill O’Neill,|Identifes how afordability has been defned and implemented in<br>the literature and UK policy debate and proposes a unifed<br>defnition across levels of decision-making. Completed.|
||Chris Sampson, George Bray||
|HTAs Around the World blog series|Patricia Cubi-Molla, Martina|An insight series on HTA arrangements country by country, each|
||Garau, Matthew Napier, Phill|with an external co-author. Three insights published in 2025|
||O’Neill, Chris Sampson,|(Kenya, Canada, Argentina), with four more in the pipeline.|
||George Bray, Henry Fong|Ongoing.|
|ECO-CHICA manuscripts (x3)|Patricia Cubi-Molla, Paul|Co-authorship of the four key ECO-CHICA deliverables with|
||Oyalo, Hannah Hussain,|LSHTM (literature review protocol, main results, deep dives, and|
||Mireia Jofre-Bonet|fnal guidance). Completed.|
|Navigating change paper|Patricia Cubi-Molla, Martina|Examines variation in the positioning of 14 HTA agencies across|
||Garau (with G Kumar, P Radu|<br>fve methodological topics and the drivers of change. Published|
||and co-authors)|in 2025 (International Journal of Technology Assessment in|
|||Health Care).|



## **Policy, Organisation and Incentives in Health Systems** 

|**Project**|**Investigators**|**Update on progress**|
|---|---|---|
|The efect of distance on accident|Sian Besley|Quantifes the relationship between travel distance and|
|and emergency department||emergency-department demand using area-level regression.|
|demand||Awaiting fnal analysis tables from external co-authors;|
|||manuscript near completion.|
|Labour productivity and efciency|Margherita Neri, Graham|Estimates a general-practice production model using stochastic|
|of general practices in England|Cookson (with E Zucchelli|frontier analysis on 316 practices (2018–2021). Being updated|
||and B Hollingsworth)|for resubmission to The European Journal of Health Economics.|
|Development of a synthetic index|Patricia Cubi-Molla,|Explores the feasibility of a synthetic index aggregating|
|of primary-care output in England|Margherita Neri, Graham|indicators of valued primary-care output, building on the Health|
||Cookson|Foundation primary-care efciency grant. Ongoing; completing|
|||the paper for submission to Applied Health Economics and|
|||Health Policy.|
|Double burden of malnutrition|Hania El Banhawi (with N|Examines the prevalence and socioeconomic determinants of|
|among mother-child pairs in|Batura and R Leiva-|mother-child double burden of malnutrition in Nigeria. Imputing|
|Nigeria|Granados, UCL)|missing data for robustness and revising for journal submission.|



## **Measuring and Valuing Outcomes** 


**----- Start of picture text -----**<br>
43<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**Project**|**Investigators**|**Update on progress**|
|---|---|---|
|Quality of life of carers of patients|David Mott, Sulayman|Completed; published in 2025 in Quality of Life Research.|
|with cystic fbrosis|Chowdhury, Patricia Cubi-||
||Molla||
|Spillover efects on informal and|Claud Theakston, David Mott|A systematic review cataloguing preference-based measures of|
|family caregivers’ utility||caregiver utility, updating Wittenberg et al. (2019). Ongoing;|
|||accepted as a poster at ISPOR Summer 2025; completing the|
|||paper for submission.|




**----- Start of picture text -----**<br>
44<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Appendix C— External presentations, 2025 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|1|8th|Chris|Health Economists’ Study Group|Bristol — Discussion of ‘Optimising allocation|50|
||January|Sampson||of healthcare resources with machine learning:||
|||||The case of personalised DR screening for||
|||||diabetes patients’ by Sasja Maria Pederson and||
|||||colleagues||
|2|9th|Mireia|HESG Meeting Winter 2025|Bristol — Outside Wage Dynamics, Turnover|20|
||January|Jofre-||and Hospital Performance - Evidence from the||
|||Bonet||English NHS’ panel discussion.||
|3|10th|Mireia|HESG Meeting Winter 2025|Bristol — ‘The efect of reductions in substance|<br>50|
||January|Jofre-||misuse service expenditure on hospital||
|||Bonet||admissions in England ’.||
|4|10th|s and the|HESG Meeting Winter 2025|Bristol — Chris Sampson chaired the panel|50|
||January|room to||session discussing ‘Can we improve quality of||
|||link||care for Child and Adolescent Mental Health||
|||methods||Services in the English NHS within a resource||
|||to||constrained environment?’||
|||implement||||
|||able||||
|||levers—||||
|||access,||||
|||continuity,||||
|||and||||
|||measurabl||||
|||e||||
|||quality—||||
|||rather||||
|||than||||
|||abstract||||
|||ideals.||||
|||(The||||
|||CAMHS||||
|||session’s||||
|||Discussan||||
|||t was||||
|||Apostolos||||
|||Tsiachista||||
|||s.||||
|5|16th|Graham|Healthcare World Stage @ Arab Health|Online — Future proofng healthcare|1700|
||January|Cookson||||
|6|22nd|Charlotte|Business Fights Poverty: Together for 2025|Online — Leadership for a Sustainable Future|200|
||January|Ashton||||
|7|23rd|Amanda|Gene People Leadership Symposium 2025 -|Virtual — Real World Evidence (RWE): what it is|—|
||January|Cole|Evidence|and why it is so important for rare diseases?||
|8|24th|Matthias|Predict FTD project kick-of event|Rotterdam — Economic analysis for Predict|—|
||January|Hofer,||FTD||
|||Sulayman||||
|||Chowdhur||||
|||y, Mireia||||




**----- Start of picture text -----**<br>
45<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|||Jofre-||||
|||Bonet||||
|9|29th|Graham|Arab Health|Conference Dubai C, Dubai World Trade Centre|—|
||January|Cookson||— Health Systems of the Future Panel||
|||||Discussion||
|10|29th|Graham|Arab Health|From AI to Value - How Data and AI can unlock|—|
||January|Cookson||value-based care models||
|11|30th|Grace|Next steps for tackling antimicrobial resistance|London — The presentation overviewed the|75|
||January|Hampson||critical priorities and next steps outlined in the||
|||||Confronting Antimicrobial Resistance: 2024 to||
|||||2029 Policy Paper and discussed solutions to||
|||||tackle AMR, including:||
|12|24th|Mikel|39th workshop of Eurordis Roundtable with|Brussels, Belgium — Achieving sustainable rare|60|
||Februar|Berdud|Companies|disease medicine markets for the common||
||y|||good? (it was the keynote presentation of a||
|||||panel entitled ‘Bridging the gap’: strengthening||
|||||European healthcare systems for equitable||
|||||patient access)||
|13|6th|Grace|AMR conference|Basel, Switzerland — Towards an EU multi-|150|
||Februar|Hampson||country PULL mechanism Pull incentives for||
||y|||new antibiotics||
|14|s:|Mireia|The Economics of Healthcare in an Ageing|Madrid, Spain — The course was a set of|30|
||26th-|Jofre-|Society: A Global Comparison|seminars addressing the major policy challenges||
||28th|Bonet||for governments and the private sector in the||
||Februar|||provision of adequate healthcare systems and||
||y|||medicine in a society that continues to live||
|||||longer.  It outlined global trends in health care,||
|||||drawing on economic analysis to provide an||
|||||understanding of the complex nature of||
|||||healthcare resource allocation, healthcare policy||
|||||design and implementation, public and private||
|||||healthcare provision as well as why data is||
|||||increasingly important in setting policy for||
|||||healthcare.||
|15|28th|Amanda|More Than You Can Imagine: Genomics and|Virtual — Patient Perspective|120|
||Februar|Cole|Rare Disease|||
||y|||||
|16||Lotte|World Evidence, Pricing and Congress 2025|Amsterdam — The UK subscription model for|75|
|||Steuten||antimicrobials: what’s next internationally?||
|17|11th|Nadine|EuroQol 5th Early Career Researcher Meeting|Barcelona, Spain — Conceptualising bolt-ons:|30|
||March|Henderso||key questions for their development and use||
|||n||||
|18|11th|Sian|EuroQoL ECR Meeting|Barcelona — Qualitative development of|40|
||March|Hodgson||candidate items for a hearing bolt-on for the||
|||||EQ-5D-5L||
|19|12th|Chris|EuroQol Academy Meeting|Barcelona — Bolt-on development: mixed-|—|
||March|Sampson||methods research programme for cognition,||
|||||vision, and hearing||
|2|13|Lotte|FIP Global Vaccination Summit|The Hague, Netherlands. — Global challenges|250|
|0|March|Steuten||in vaccination from 2025 to 2030: Is pharmacy||




**----- Start of picture text -----**<br>
46<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|||||part of the solution? Economic value of||
|||||vaccines, funding models”||
|21|20th|Amanda|Global Payer Forum (Webinar 3: Will a Focus on|Virtual|230|
||March|Cole|Value Drive the Future of our Healthcare|||
||||Systems?|||
|22|20th|Patricia|London Health Economics Group (LHEG)|ABPI-OHE ofces — Development of a|35|
||March|Cubi-|meeting|synthetic index of primary care output in||
|||Molla||England: a feasibility study||
|2|26th|Chris|Progress Educational Trust|Online — “Is Fertility Treatment A Solution To|—|
|3|March|Skedgel||Population Decline?”||
|24|27th|Martina|Sanof Rare Forum|Sanof ofce in Boston — Rarity in value|60|
||March|Garau||assessments||
|2|27th|Chris|NICE Conference|Manchester — Methods and processes that|150|
|5|March|Sampson||keep pace with change||
|2|9th|Lotte|LSE Market Access Academy|Outcomes-Based Payment Models: if not now,|40|
|6|April|Steuten||then when?||
|27|15th|Charlotte|Abu Dhabi Global Health Week|Abu Dhabi, UAE — Building Data Driven|60|
||April|Ashton||Healthcare Systems||
|2|16th|Charlotte|Abu Dhabi Global Health Week|Abu Dhabi, UAE — Personalised Medicine,|80|
|8|April|Ashton||Population Health and the Preventative Agenda:||
|||||Who Pays the Bill?||
|2|28th|Patricia|Seminar at the University of Pablo Olavide|Faculty of Economics, Savilla, Spain — “From|25|
|9|April|Cubi-||Discount Rates to Patient Voices: Exploring||
|||Molla||Methodological Evolution in Health Technology||
|||||Assessment Globally“||
|3|1st May|Charlotte|Understanding research impact with BMJ|of presentation   From Research to Impact: The|165|
|0||Ashton|Impact Analytics: Tracking the real-world impact|<br>Infuence of Health Economics Around the||
||||of medical and health research|World’||
|31|8th|Simon|Adult Immunisation Board|Warsaw — Vaccine impact assessment and|—|
||May|Brassel||economic value of vaccination in aging adults||
|3|14th|Graham|ISPOR Montreal 2025|Montreal, Canada — Plenary Session: Drug|50|
|2|May|Cookson||Price Controls—What Are the Unintended||
|||||Consequences to Innovation?||
|3|14th|Grace|ISPOR Montreal 2025|Montreal, Canada — New Approaches to|50|
|3|May|Hampson||Sustainable Healthcare: How Can Environmental||
|||||Impact Data Contribute to Whole Health?”||
|3|14th|Lotte|ISPOR Montreal 2025|Montreal, Canada — Introducing HEMA: An|—|
|4|May|Steuten||International Working Group for Principled||
|||||Assessment of Novel HTA Methods and||
|||||Processes||
|3|15th|Lotte|ISPOR Montreal 2025|Montreal, Canada — The Value Flower: Evolving|—|
|5|May 14|Steuten||the Framework for Comprehensive Value||
|||(moderato||Assessment”||
|||r)||||




**----- Start of picture text -----**<br>
47<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|3|15th|Lotte|ISPOR Montreal 2025|Montreal, Canada — “Understanding and|—|
|6|May 14|Steuten||Rewarding the Full Value of Long-Acting Session||
|||(moderato||Overview||
|||r)||||
|37|16. May|Matthias|ISPOR Montreal 2025|Montreal, Canada — Novel value elements:|—|
|||Hofer||Developing and applying a pragmatic value||
|||||framework in early stages of product||
|||||development [Poster]||
|3|19 May|Martina|LSE market access academy|LSE, London — Navigating change:|40|
|8||Garau||understanding HTA reforms and other factors||
|||||impacting the future of HTA||
|3|May|Mireia|American-European Health Economics Study|Department of Economics, Oxford University —|<br>50|
|9|28th|Jofre-|Group - IX Edition|Biosimilars and Price Competition in US||
|||Bonet||Pharmaceutical Markets||
|4|5th|Amanda|Westminster Health Forum policy conference:|Virtual — The importance of early detection,|—|
|0|June|Cole|Priorities for rare disease diagnosis, care and|diagnosis and care coordination||
||||treatment in England|||
|41|9th|Mikel|Access Forum US 2025|AT&T Executive Conference Center, Austin,|16|
||June|Berdud||Texas, US Presentation Title: Unlocking the full||
|||||value of biosimilars: Policy challenges and||
|||||solutions to market sustainability — Unlocking||
|||||the full value of biosimilars: Policy challenges||
|||||and solutions to market sustainability||
|4|9th.|Matthias|HiPrix Consortium meeting|Lisbon — Interim results and progress on OHE|30|
|2|and 10.|Hofer||contribution to HiPrix project||
||June|||||
|4|16th|Martina|HTAi meeting|Buenos Aires — Evidence Assessment|—|
|3|June|Garau||Frameworks and Economic Modelling in Rare||
|||||Diseases: A Stakeholder Survey Exploring||
|||||Current Practices in HTA||
|4|17th|Mikel|XLIV Jornadas de Economía de la Salud of the|Universidad Complutense, Madrid, Spain —|21|
|4|June|Berdud|Spanish Health Economics Association (AES).|Pathways for innovation and sustainability in the||
||||Preconference workshop.|development and access to new medicines:||
|||||alternative payment schemes and other courses||
|||||of action.||
|4|17th|Martina|HTAi meeting|Buenos Aires — HTAi Rare Disease Interest|50|
|5|June|Garau||Group (RDIG): Overview of the group’s||
|||||activities and fndings from a survey.||
|4|17-19|Charlotte|Global Sustainable Development Congress|Istanbul — Co-chairs of health and wellbeing|100|
|6|June|Ashton|2025|track||
|||and Grace||||
|||Hampson||||
|47|17-19|Charlotte|Global Sustainable Development Congress|Istanbul — Health Economics: The missing link|100|
||June|Ashton|2025|in sustainable development at the Global||
|||and Grace||Sustainable Development Congress 2025,||
|||Hampson||What was your presentation about? Integrating||
|||||health economics into broader development||
|||||strategies to ensure long-term impact and||
|||||sustainability.||




**----- Start of picture text -----**<br>
48<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|4|7 June|Lotte|Colloquium at the French Ministry of Health|Virtual — The socio-economic value of adult|100|
|8||Steuten||vaccination programmes||
|4|17th|David|ISPOR Webinar|Online/Virtual — Designing DCEs to Estimate|120|
|9|June|Mott||Utilities||
|5|30th|David|Pre-HESG Educational Session “Introducing an|Brighton — Developments in health valuation &|50|
|0|June|Mott|EQ-5D-5L value set for the UK“|the UK EQ-5D-Y-3L||
|51|18th|Simon|AES 2025|Madrid — The Socioeconomic Value of Adult|—|
||June|Brassel||Immunisation||
|52|19th|Mikel|XLIV Jornadas de Economía de la Salud of the|Universidad Complutense, Madrid, Spain —|120|
||June|Berdud|Spanish Health Economics Association (AES).|New payment and pricing models for innovation||
||||Panel discussion.|and sustainability in pharmaceutical markets.||
|5|19th|Mikel|XLIV Jornadas de Economía de la Salud of the|Universidad Complutense, Madrid, Spain —|30|
|3|June|Berdud|Spanish Health Economics Association (AES).|Unlocking Access: Overcoming Barriers and||
||||Oral presentation.|Harnessing Enablers for Innovative Payment||
|||||Models for Pharmaceutical Innovation in Europe.||
|5|20th|Mikel|XLIV Jornadas de Economía de la Salud of the|Universidad Complutense, Madrid, Spain —|25|
|4|June|Berdud|Spanish Health Economics Association (AES).|Implementation Costs and Benefts of||
||||Oral presentation.|Innovative Payment Models: an assessment of||
|||||four case studies in Europe||
|5|25 June|Grace|Breaking Financial Barriers: Sustainable|Online — Breaking Financial Barriers:|—|
|5||Hampson|Healthcare Financing for RTRS Patients|Sustainable Healthcare Financing for RTRS||
|||||Patients||
|5|30th|Nadine|HESG Summer 2025|Doubletree Hilton, Brighton — Discussion of|30|
|6|June|Henderso||“Value of investment in cycleways as a means to||
|||n||improve population physical activity and||
|||||alleviate inequalities“||
|57|30 June|Sian|HESG|Brighton — Heterogeneous efects of primary|—|
|||Hodgson||care funding on access to care: A longitudinal||
|||(as||study of English general practice, 2014-2022||
|||Discussan||||
|||t), Hannah||||
|||Hussain -||||
|||as chair||||
|5|1st July|Matthew|HESG|Brighton — Discussion of: A systematic review|—|
|8||Napier||of using SROI on investment within healthcare||
|||||service evaluations: Methodological||
|||||opportunities and challenges||
|5|1st July|Chris|HESG summer 2025|Brighton, UK — Discussion of ‘Identifying key|25|
|9||Sampson||patient characteristics for the||
|||||acknowledgement of patient heterogeneity in||
|||||economic evaluations in severe mental illness’||
|6|1st July|Sian|HESG Summer 2025|Brighton — Heterogeneous efects of primary|—|
|0||Hodgson||care funding on access to||




**----- Start of picture text -----**<br>
49<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|61|1st July|Sian|HESG Summer 2025|Brighton — Hospital Ownership and Quality: A|—|
|||Hodgson||Decomposition Analysis Using Process and||
|||||Outcome Indicators||
|6|2nd July|Event:|HESG summer meeting|Brighton, UK — Methods for the Economic|—|
|2||HESG||Evaluation of Health Impacts of Climate Action:||
|||summer||When, Why, and How Best to Use Them? A||
|||meeting||Literature Review.||
|6|2nd July|Mireia|HESG Summer 2025|Brighton — Building a synthetic population to|—|
|3||Jofre-||assess the health impacts of local climate||
|||Bonet||change policies in England.||
|6|1st July|Amanda|HESG|Brighton — Early Career Researcher session|—|
|4||Cole||“Health Economics Career Paths: The Good, the||
|||||Bad and the Ugly“||
|6|2nd July|Amanda|HESG|Brighton — The ‘Canberra Hypothesis’ 50 years|—|
|5||Cole||on: medicine prices and the economics of the||
|||||pharmaceutical industry||
|6|4th July|Chris|CERSI PGx Workshop|Online — An approach to estimating the value|—|
|6||Sampson||of pharmacogenomics to the UK Economy||
|67|17 July|Patricia|NICE Technical Forum - Seminar|online — Navigating change: a comparative|—|
|||Cubi-||analysis of Health Technology Assessment||
|||Molla||reforms across agencies and their||
|||||interdependencies.||
|6|21. July|Matthias|IHEA Location: Bali|Bali — Implementation costs and benefts of|40|
|8||Hofer||innovative payment models||
|||Event:||||
|||IHEA||||
|||Location:||||
|||Bali||||
|6|21. July|Matthias|IHEA|Bali — How to incorporate a societal|—|
|9||Hofer||perspective in Asia-Pacifc decision making?||
|||Event:||What was your presentation about?||
|||IHEA||Characterisation of the status quo and ways to||
|||||foster the consideration of a societal||
|||||perspective in HTA decision making in Asia-||
|||||Pacifc countries. Part of the BRAVER||
|||||consultancy project.||
|70|21. July|Matthias|IHEA|Bali Presentation Title: Overcoming barriers and|—|
||Present|Hofer||harnessing enablers for innovative payment||
||er:|Event:||models for pharmaceutical innovation in Europe||
||Matthia|IHEA||— Overcoming barriers and harnessing||
||s Hofer|||enablers for innovative payment models for||
||Event:|||pharmaceutical innovation in Europe||
||IHEA|||||
|71|21st|Chris|IHEA 2025|Bali, Indonesia — Decision Analysis for|—|
||July|Sampson||Planetary and Human Health: Waste||
|||||Management in the Life Sciences Industry||
|72|23rd|Mireia|IHEA 2025|Bali, Indonesia — Guideline Development: More|<br>—|
||July|Jofre-||Than Just Another Checklist||
|||Bonet||||




**----- Start of picture text -----**<br>
50<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|73|23rd|Mireia|IHEA|Bali, Indonesia — Methods for the Economic|—|
||July|Jofre-||Evaluation of Health Impacts of Climate Action:||
|||Bonet||When, Why, and How Best to Use Them? A||
|||||Literature Review||
|74|11th|Hannah|Health Economics for Policy Research Seminar|Virtual — Enhancing health-related quality of|—|
||Septem|Hussain|Series|life (HRQoL) assessment for economic||
||ber|||evaluation in dementia populations||
|75|18th|Chris|Inaugural Resource Allocation Symposium|Birmingham, UK — Forecasting the value of a|80|
||Septem|Sampson||system-shift in health and social care: making a||
||ber|||case for investment with economic evaluation||
|76|22nd|Patricia|X Programa Experto en Politica Sanitaria y|Palma de Mallorca — Competencia, regulación|—|
||Septem|Cubi-|Farmacoeconomia: es más siempre mejor?|y gasto: ¿siempre mas es mejor? Visión||
||ber|Molla||internacional||
|77|24th|Chris|Concordia Summit, NYC|“How to fnd national cardiovascular health|—|
||Septem|Skedgel||action plans“||
||ber|||||
|78|25th|Chris|42nd EuroQol Plenary|Vienna, Austria — Discussion of ‘Comparison of|<br>—|
||Septem|Sampson||the EQ-5D-5L cognition bolt-on and EQ-HWB||
||ber|||cognition dimensions: Results from EQ-||
|||||DAPHNIE data in China and Japan||
|79|24th|Chris|Concordia Summit, NYC|“How to fnd national cardiovascular health|—|
||Septem|Skedgel||action plans“||
||ber|||||
|8|25th|Chris|42nd EuroQol Plenary|Vienna, Austria|—|
|0|Septem|Sampson||||
||ber|||||
|81|1st|Grace|Rising to the Challenge: Utilizing Diagnostics to|Geneva — Taking STRIDES: The value of|—|
||Octobe|Hampson|Combat Infectious Diseases and AMR|diagnostics against AMR||
||r|||||
|8|1st|Lotte|GAMRIC Conference|London: — Taking Strides: The value of|—|
|2|Octobe|Steuten||diagnostics against AMR||
||r|||||
|8|1st|Martina|CIRS meeting|London|—|
|3|Octobe|Garau||||
||r|||||
|8|7th|Lotte|Roundtable The Unseen Burden of Migraine:|, Paris — Roundtable participant: Lotte was|—|
|4|Octobe|Steuten|Impacts on Care, Productivity, and Economic|invited to a private roundtable, which was||
||r||Growth in an Aging Society.|organized with funding from Pfzer, conveneing||
|||||leaders from across sectors and disciplines to||
|||||explore migraine’s multi-faceted impact on||
|||||healthcare systems, workplace productivity and||
|||||economic growth, quality of life, and caregiving||
|||||in a rapidly aging world. The interactive||
|||||discussions aim was to identify impactful||
|||||solutions and policy actions to ensure that||
|||||those afected by migraine receive the attention||
|||||and care needed.||




**----- Start of picture text -----**<br>
51<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|8|8th|Lotte|Building healthy, productive workforces for our|Paris — Lotte was invited to provide health|30|
|5|Octobe|Steuten|21st century  Closed doors meeting, hosted by|economics insights on the value of prevention||
||r||OECD and the Global Coalition on Aging|||
|8|8th|Lotte|Pfzer’s Adult Vaccine-Preventable Respiratory|Virtual — Health system impacts of vaccine|35|
|6|Octobe|Steuten|Disease (VPRD) Advisory Panel session|uptake and broader socio-economic value of||
||r|||adult vaccination||
|87|12th|Lotte|Title:  World Health Summit|Berlin — World Health Summit|—|
||Octobe|Steuten||||
||r|||||
|8|14th|Chris|“Severity Matters“ Forum|Online — “The NICE Severity Modifer and|12|
|8|Octobe|Skedgel||Public Preferences around Severity“||
||r|||||
|8|15th|Helen|EACS Paris 2025:||—|
|9|Octobe|Hayes||||
||r|||||
|9|15th|Lotte|World Vaccine Congress Europe 2025|Amsterdam, The Netherlands — Lotte|200|
|0|Octobe|Steuten||moderated a session on the importance of and||
||r|||methodologies for evaluating the broader value||
|||||of vaccines||
|91|18th|Simon|Global Infuenza Initiative (GII)- Annual Meeting|Valencia|—|
||Octobe|Brassel|Location: Valencia|||
||r|||||
|9|21st|Lotte|GSK/ViiV Healthcare Preventing the Cost of|London — This event – sponsored by GSK and|—|
|2|Octobe|Steuten|Inaction policy roundtable discussion|ViiV Healthcare in partnership with the Terrence||
||r|||Higgins Trust, and co-hosted by Baroness||
|||||Ritchie & Richard Angell, CEO Terrance Higgins||
|||||Trust – brought together parliamentarians,||
|||||ofcials, patient groups and experts to explore||
|||||how we can move from ambition to action in||
|||||embedding a prevention-frst ethos across the||
|||||health system. Lotte used this  opportunity to||
|||||share experiences, surface practical solutions||
|||||and identifed where collective action can make<br>the greatest diference.||
|9|22nd|Lotte|SMDM Virtual Course: Handling Uncertainty in|Online — Interpret and report results of|27|
|3|Octobe|Steuten|HTA Processes|uncertainty analyses for HTA.||
||r|||||
|9|28th|Lotte|World Orphan Drug Congress 2025|Amsterdam — Panel title: Expanding patient|80|
|4|Octobe|Steuten||access to multi-indication medicines in Europe||
||r|||through innovative agreements||
|9|10th|Lotte|ISPOR Europe 2025|Glasgow, UK — “Integrating Capacity-|—|
|5|Novem|Steuten||Enhancing Innovations in Healthcare Systems:||
||ber|||Are Current Methods Adequate to Demonstrate||
|||||the Impact on Efciency and Capacity?”||
|9|6th|Simon|European Policy Center Roundtable|Brussels|—|
|6|Novem|Brassel||||
||ber|||||




**----- Start of picture text -----**<br>
52<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|97|10th|Mikel|ISPOR Europe 2025|Glasgow, UK|—|
||Novem|Berdud||||
||ber|||||
|9|11th|Lotte|ISPOR Europe 2025|Glasgow, UK — More Than a Long Shot:|250|
|8|Novem|Steuten||Rethinking the ROI of Modern Medicines for||
||ber|and David||Public Health||
|||Mott||||
|9|11th|Lotte|ISPOR Europe 2025|Glasgow, UK — Can We Have It “Whole”?|80|
|9|Novem|Steuten||Barriers and Opportunities for Embracing a||
||ber|and Simon||Whole Health Perspective in HEOR||
|||Brassel||||
|10|11th|Sian|ISPOR Europe 2025|Glasgow, UK|—|
|0|Novem|Hodgson||||
||ber|||||
|10|11th|Mireia|ISPOR Europe 2025|Glasgow, UK — The ECOnomiC Valuation of|50|
|1|Novem|Jofre-||the Health Impacts of Climate Action (or||
||ber|Bonnet||Inaction): The ECO-CHICA Guidelines||
|10|11th|Grace|ISPOR Europe 2025|Glasgow, UK — Adding Nature’s Petal to the|—|
|2|Novem|Hampson||Value Flower: Can Inclusion of Environmental||
||ber|||Impact in HTA Aid the Race to Net Zero?||
|10|11th|Graham|ISPOR Europe 2025|Glasgow, UK — Increasing Transparency of|—|
|3|Novem|Cookson||Public Funding in Pharmaceutical Research and||
||ber|||Development Reporting||
|10|11th|Martina|ISPOR Europe 2025|Glasgow, UK — A Systematic Review of|60|
|4|Novem|Garau||Economic Modeling Challenges and Proposed||
||ber|||Solutions for Rare Disease Technologies: An||
|||||HTAi RDIG Initiative||
|10|11th|Mikel|ISPOR Europe 2025|Glasgow, UK — How Can We Make Innovative|240|
|5|Novem|Berdud||Payment And Pricing Schemes a “Win” From All||
||ber|||Perspectives?||
|10|11th|George|ISPOR Europe 2025|Glasgow, UK — Science At PACE? A multi-|—|
|6|Novem|Bray||stakeholder developed framework for||
||ber|||Accelerated Patient Access to Cancer Care||
|10|11th|Grace|ISPOR Europe 2025|Glasgow, UK — Novel Antibiotic Value Elements|10|
|7|Novem|Hampson||in the Context of Antimicrobial Resistance||
||ber|||RECOGNISING THE VALUE OF NOVEL||
|||||ANTIBIOTICS||
|10|12th|Helen|ISPOR Europe 2025|Glasgow, UK — The Cost of Complacency:|10|
|8|Novem|Hayes||Projecting the Burden of HIV Care in Eight||
||ber|||European Countries||
|10|12th|Brittany|ISPOR Europe 2025|Glasgow, UK — Overcoming Barriers and|10|
|9|Novem|Darrow||Harnessing Enablers for Innovative Payment||
||ber|||Models for Pharmaceutical Innovation in Europe.||
|11|12th|George|ISPOR Europe 2025|Glasgow, UK — Fiscal Health modelling of C19|10|
|0|Novem|Bray||in the UK.||
||ber|||||




**----- Start of picture text -----**<br>
53<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**#**|**DATE**|**PRESENT**|**EVENT**|**LOCATION / TITLE**|**AUDIE**|
|---|---|---|---|---|---|
|||**ER**|||**NCE**|
|111|12th|Hania El|ISPOR Europe 2025|Glasgow, UK — The Enduring Economic Burden|10|
||Novem|Banhawi||of COVID-19 and the Value of Vaccination||
||ber|||Strategies in High-Income Countries.||
|11|12th|Matthew|ISPOR Europe 2025|Glasgow, UK — The Socioeconomic Value of|20|
|2|Novem|Napier||Adult Respiratory Immunization Programs in||
||ber|||Spain: How Much Can We Gain From Expanding||
|||||Prevention Eforts?||
|11|12th|Martina|ISPOR Europe 2025|Glasgow, UK — Science at PACE? A|30|
|3|Novem|Garau||Multistakeholder Developed Framework for||
||ber|||Accelerated Patient Access to Cancer Care||
|11|12th|David|ISPOR|Glasgow|—|
|4|Novem|Mott||||
||ber|||||
|11|13th|Chris|National Pharmacogenomics and Medicines|Manchester|120|
|5|Novem|Sampson|Optimisation Network of Excellence event|||
||ber|||||
|11|18th|Lotte|TASPOR Annual Meeting 2025|Taiwan (virtual) — UK Approaches to Cancer|356|
|6|Novem|Steuten||Combination Therapy Reimbursement and||
||ber|||Emerging Value Attribution Frameworks: Lessons||
|||||from the UK and the EU||
|11|18th|Lotte|World Antimicrobial Resistance Week (WAAW)|Geneva - virtual — The Global Value of|821|
|7|Novem|Steuten|2025|Diagnostics: Stewardship and Appropriate Use,||
||ber|||the Broader Healthcare System, and Beyond||
|11<br>8|11th<br>Novem<br>ber|Mireia<br>Jofre-<br>Bonnet|ISPOR Europe 2025|Glasgow, UK — Methods for the Economic<br>Evaluation of Health Impacts of Climate Action.<br>A Scoping Review.|20|
|11|13th|Mikel|Lecture at City, St Georges University of|London|22|
|9|Novem|Berdud|London|||
||ber|||||
|12|11th|Mireia|Invited guest lecture for the Executive MSc|LSE Campus, London|50|
|0|Decem|Jofre-|Programme in Health Policy, Department of|||
||ber|Bonet|Health Policy, LSE|||
|12|3rd|Lotte|Healthcare’s Competitive Future: From Reactive|Paris, France|300|
|1|Decem|Steuten|Systems to Economic Catalysts (by Business at|||
||ber||OECD Health Forum)|||
|12|5th|Simon|British Embassy Event Riga|Riga|25|
|2|Decem|Brassel||||
||ber|||||




**----- Start of picture text -----**<br>
54<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Appendix D — OHE staff membership of advisory panels, boards and committees 

## **Advisory Panels** 

## **Health Foundation** 

- Member of the Steering Committee for NHS Workforce Retention Project – Graham Cookson 

## **HTAi** 

- Working Group on early HTA – Amanda Cole 

- **ISPOR** 

- Member of the ISPOR Health Science Policy Council (Science/Research Committee) – Amanda Cole 

- • Member of the ISPOR Health Science Policy Council (Task Force Review Committee) – Lotte Steuten 

- • Chair Audit Committee – Lotte Steuten 

## **CIRS** 

- Member of the Health Technology Assessment Committee – Lotte Steuten 

- Chair of the Vaccines Committee – Lotte Steuten 

## **NHS England** 

- Primary Care Transformation Programme: Quantitative Working Group – Graham Cookson 

- **Governments** • Member of the Health Economics working group advising the Spanish Ministry of Health on the update of the national strategy for rare diseases - Mikel Berdud 

- Member of the Patient Advisory Group for the Department of Health and Social Care (DHSC)’s Rare Disease Action Plan 2025 – Amanda Cole 

## **NIHR** 

- Steering Committee Member for NIHR/HS&DR Project No. 8/17/1934 – Graham Cookson 

- Steering Committee for the LOGiC – Long term Outcomes for Gender Identity in Children Study – funded by NIHR. Sites: Portman-NHS; UCL; U. Liverpool, U. Cambridge, UCLH – Mireia Jofre-Bonet 

- Steering Committee for ADVANCE – National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience – King’s College London – Mireia Jofre-Bonet 

- Steering Committee for Preventing Childhood Blindness through Integration of Eye Health into Child Health Policies and Systems -Programme Name: Global Health (GH) - 22/153 Global HPSR Call 3 - London School of Hygiene & Tropical Medicine – Mireia Jofre-Bonet 

- Study Steering Committee (SSC) member for CONCORD2: A study into the care coordination of rare conditions –  funded by NIHR, Grant no. NIHR205991- Amanda Cole 

## **Other advisory boards** 

- Member of CMAC Independent Advisory Board convened by University of Strathclyde – Nadine Henderson 

- • Member of the Advisory Board of a Review of the UK labour market for health economists on behalf of Health Economists’ Study Group, led by Matt Sutton and Mark Sculpher – Mireia Jofre-Bonet 

- Member of Genetic Alliance UK’s Patient Empowerment Group (PEG) - Amanda Cole 

## **Scientific Committees** 

- EuHEA 2024 - Mireia Jofre-Bonet 

- HESG Summer 2025 – Chris Sampson, Amanda Cole, Chris Skedgel, Helen Hayes, Lotte Steuten, Martina Garau, Matthew Napier, Mireia Jofre-Bonet, Nadine Henderson, Sian Hodgson 

- HESG Winter 2026 – Chris Sampson, Mireia Jofre-Bonet 

- AES 2025 - Patricia Cubi-Molla 

## **Interest Groups/Task Forces** 

## **Clinton Foundation Global Initiative** 

- Climate x Health Committee (member) – Charlotte Ashton 

## **Women in Global Health - UK Chapter** 

- Committee (member) – Charlotte Ashton 

## **IHEA** 


**----- Start of picture text -----**<br>
55<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

- Mental Health Economics Special Interest Group (Lead Convenor)– Chris Sampson 

## **ISPOR** 

- ISPOR Special Taskforce on Value-Based Healthcare (Co-Chair)– Lotte Steuten 

- • Statistical Methods in Health Economics and Outcomes Research Special Interest Group (member) – Graham Cookson 

- • Oncology Special Interest Group (member) – Graham Cookson 

- • Rare Disease Special Interest Group (member) – Graham Cookson 

- Health Preference Research Group (member) – David Mott 

- Digital Health Special Interest Group (member) – Simon Brassel 

- Global Access to Medical Innovation Special Interest Group (GAMI SIG) (member) – Amanda Cole 

- • Exploring Actionable Solutions for Environmental Sustainability and Climate Resilience in HEOR – Grace Hampson (member) 

- • Exploring Actionable Solutions for Environmental Sustainability and Climate Resilience in HEOR – Mireia Jofre-Bonet (member) 

## **EuroQol** 

- Descriptive Systems Working Group (member) – Chris Sampson 

- Valuation Working Group (member) - David Mott 

## **HTAi** 

- Steering Committee of the HTAi Rare Disease Interest Group (RDIG) (member) - Martina Garau 

- • Economic modelling RDIG subgroup (Co-Lead) – Martina Garau 

## **Editorial Roles** 

## **Value in Health** 

- Associate Editor – Lotte Steuten 

**Applied Health Economics and Health Policy Journal** 

- Editorial Board Member – Lotte Steuten 

- Editorial Board Member – Patricia Cubi-Molla 

## **PharmacoEconomics** 

- Editorial Board Member – Chris Skedgel 

- **PLOS One** 

- Editorial Board Member – Mireia Jofre-Bonet 

## **Orphanet journal of rare diseases** 

- Section editor (health economics) – Mikel Berdud 

## **Patient Preference and Adherence** 

- Editorial Board Member – David Mott 

## **Grant Panel Advisory Groups** 

## **NICE** 

- Expert Advisers Panel for the Centre for Guidelines – Mireia Jofre-Bonet 

## **NIHR** 

- Invention for Innovation (i4i) Product Development Awards Committee B (Member) – Chris Sampson 

- **UKRI/ESRC/MRC** 

- ESRC/UKRI Peer Review College – Mireia Jofre-Bonet 

- ESRC/UKRI Peer Review College– Chris Sampson 

- ESRC/UKRI Peer Review College– Patricia Cubi-Molla 

## **Novartis/Spanish Health Economics Association (AES)** 

• Panel for the research grant “Becas de investigacion en Economia de la Salud”, awarded by the Spanish Health Economics Association (AES), funder: Novartis – Patricia Cubi-Molla 

## **“La Caixa” Foundation** 

- Peer Review of Grants by “la Caixa” Foundation, Spain – Mireia Jofre-Bonet 

## **Visiting Positions for OHE Staff** 

## **City St George’s, University of London** 

- Honorary Visiting Professor, Department of Economics – Lotte Steuten 


**----- Start of picture text -----**<br>
56<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

- Honorary Visiting Professor, Department of Economics – Graham Cookson 

- Honorary Visiting Professor, Department of Economics – Mireia Jofre-Bonet 

- Honorary Senior Research Fellow, Department of Economics – Patricia Cubi-Molla 

- Honorary Senior Research Fellow in the Department of Economics at City St George’s, University of London. - Mikel Berdud 

## **Fred Hutch Cancer Research Center, University of Washington** 

- Affiliate Investigator – Lotte Steuten 

**Public University of Navarra** 

- Visiting Researcher – Mikel Berdud 

- **University College London (UCL)** 

- Honorary Professor of Practice – Amanda Cole 

## **University of East Anglia** 

- Honorary Senior Fellow – Chris Skedgel 

## **University of Surrey** 

- Visiting Professor – Graham Cookson 

- **Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain** 

- Senior Associate Researcher – Mireia Jofre-Bonet 

## **School of Medicine, University of Nottingham** 

- Honorary Associate Professor – Chris Sampson 

- **University of Hertfordshire** 

- Visiting Researcher – Chris Sampson 

## **Memberships** 

Many OHE researchers are also members of associations such as **ISPOR, IHEA, HESG, AES, EuroQoL** ,,and **iHTA** . 


**----- Start of picture text -----**<br>
57<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## Appendix E— Funding in 2025 

## **Projects won in 2025** 

|**FUNDER**<br>**EUROPEAN**<br>**COMMISSION**<br>**EUROPEAN**<br>**COMMISSION**<br>**THE UNIVERSITY OF**<br>**SUSSEX**<br>**UNIVERSITY OF**<br>**MANCHESTER**<br>**INNOVATE UK**<br>**NESTA**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**NATIONAL INSTITUTES**<br>**OF HEALTH**<br>**CML ADVOCATES**<br>**NETWORK**<br>**EUROQOL RESEARCH**<br>**OXYGEN STRATEGY**<br>**TOTAL**|**Project Title**<br>**Theme**<br>**Year won**<br>**Project**<br>**Budget**|
|---|---|
||TEN4CARE<br>VADM<br>Sep-25<br>£306,544|
||PREDICT FTD<br>VADM<br>Jan-25<br>£263,512|
||Green Healthcare Hub Decarbonising<br>H&SC)<br>POIHS<br>Oct-25<br>£213,455|
||CEiRSI Economic Impact In Silico<br>EoI<br>Jul-25<br>£124,994|
||CERSI-PGx Value of pharmacogenomics to<br>the UK<br>VADM<br>Jan-25<br>£79,932|
||Commercial Case for ALS<br>EoI<br>Jul-25<br>£39,996|
||Does a spoonful of honey improve a barrel<br>of tar? 33333 vs 33333+1<br>MVO<br>Oct-25<br>£23,752|
||Assessing bolt-ons in cognition (ABC)<br>MVO<br>Jan-25<br>£21,962|
||ModEx advisory panel<br>VADM<br>Jan-25<br>£10,000|
||Extension of CML patient preference study<br>MVO<br>Aug-25<br>£9,713|
||OPUF bolt-on valuation<br>MVO<br>Sept-25<br>£3,995|
||Severity Matters Roundtable<br>MVO<br>Oct-25<br>£2,000<br>£1,099,805|



_*Networks built through previous European projects continued to pay dividends: in 2025 OHE secured a further HORIZON grant (TEN4CARE) and submitted further applications._ 

## **Projects won before 2025 and still live** 

|**FUNDER**<br>**CML ADVOCATES**<br>**NETWORK**<br>**EUROPEAN**<br>**COMMISSION**<br>**ACUTE LEUKAEMIA**<br>**ADVOCATES NETWORK**<br>**LONDON SCHOOL OF**<br>**HYGIENE & TROPICAL**<br>**MEDICINE**<br>**ACUTE LEUKAEMIA**<br>**ADVOCATES NETWORK**<br>**ACUTE LEUKAEMIA**<br>**ADVOCATES NETWORK**|**Project Title**<br>**Theme**<br>**Year won**<br>**Project**<br>**Budget**|
|---|---|
||CML patient preference study<br>MVO<br>Jul-24<br>£377,578|
||EU HORIZON HIGH-PRIX<br>EoI<br>Mar-23<br>£354,263|
||Patient preferences for Leukaemia<br>treatments: UK/US/EU4 1L all phases<br>MVO<br>Nov-23<br>£210,477|
||ECO-CHICA Valuing the Health Impact of<br>Climate Actions<br>MVO<br>Dec-24<br>£156,284|
||Acute Leukaemia carer preference study<br>MVO<br>Nov-23<br>£149,876|
||Patient preferences for Leukaemia<br>treatments: US/EU4 R/R all phases<br>MVO<br>Jan-23<br>£105,117|




**----- Start of picture text -----**<br>
58<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**FUNDER**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**ACUTE LEUKAEMIA**<br>**ADVOCATES NETWORK**<br>**HIGH FLOW THERAPY UK**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**TOTAL**|**Project Title**<br>**Theme**<br>**Year won**<br>**Project**<br>**Budget**<br>Development and testing of a hearing bolt-<br>on<br>MVO<br>Jan-21<br>£77,456<br>Patient preferences for Leukaemia<br>treatments: UK R/R phases 5<br>MVO<br>Jun-23<br>£73,789<br> <br>High Flow Therapy Post AECOPD<br>VADM<br>Oct-24<br>£71,159<br>Exploring the use of the OPUF tool for<br>valuing EQ-5D Y 3L<br>MVO<br>Jan-22<br>£63,310<br>EQ-5D Bolt-on Development<br>MVO<br>Jan-19<br>£57,700<br>Bolt-on Conceptual<br>MVO<br>Sep-23<br>£32,599<br>Estimating an EQ-5D-Y-3L set in the United<br>Kingdom<br>MVO<br>Jul-23<br>£7,650<br>£1,739,226|
|---|---|



## **Projects won before 2025 and closed during 2025** 

|**FUNDER**<br>**IFPMA**<br>**THE HEALTH**<br>**FOUNDATION**<br>**AMICUS THERAPEUTICS**<br>**CURTA, INC**<br>**PARKINSON’S UK**<br>**IFPMA**<br>**UCL**<br>**TOTAL**|**Project Title**<br>**Theme**<br>**Year won**<br>**Project**<br>**Budget**|
|---|---|
||Socio-economic value of adult vaccination<br>VADM<br>Dec-22<br>£467,373|
||Efciency and Labour Productivity in Primary<br>Care<br>POIHS<br>Mar-21<br>£410,325|
||<br>Diversity of supply for rare disease<br>medicines<br>EoI<br>Oct-24<br>£84,513|
||Biosimilar Market Dynamics:  A Review and<br>Simulation Model<br>EoI<br>Jun-23<br>£23,650|
||PwP Mindfulness app<br>VADM<br>Sep-21<br>£15,318|
||Extension of Socio-economic value of adult<br>vaccination Flu Abstract<br>VADM<br>Apr-24<br>£2,598|
||UCL Health Exec Ed Program<br>EoI<br>Nov-24<br>£1,969<br>£1,005,745|



## **Grant and project pipeline at year end** 

|**FUNDER**<br>**EUROPEAN COMMISSION**<br>**EUROPEAN COMMISSION**<br>**NIHR**<br>**EUROPEAN COMMISSION**<br>**EUROPEAN COMMISSION**<br>**EUROPEAN COMMISSION**<br>**THE FLEMING INITIATIVE**|**Project Title**<br>**Value**<br>**Probability %**<br>**Proj. Adj.**<br>**Value**|
|---|---|
||PHAGE4EYE<br>£323,296<br>10<br>£32,330|
||SMARTCell<br>£305,790<br>10<br>£30,579|
||Expected Value of Environmental<br>Information<br>£295,000<br>15<br>£44,250|
||FARM2FORM<br>£280,000<br>20<br>£56,000|
||CAT Shine<br>£233,333<br>5<br>£11,667|
||NANOPANTHER<br>£208,333<br>5<br>£10,417|
||AMR Strategic Policy TFI<br>£150,000<br>50<br>£75,000|




**----- Start of picture text -----**<br>
59<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**FUNDER**<br>**CHANGE INITIATIVE -**<br>**COMPANY PARTNERSHIP**<br>**QUEEN MARY UNIVERSITY OF**<br>**LONDON**<br>**ACUTE LEUKAEMIA**<br>**ADVOCATES NETWORK**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROPEAN COMMISSION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**NIHR**<br>**VERIAN**<br>**EUROQOL RESEARCH**<br>**FOUNDATION**<br>**NIHR**<br>**EUROPEAN COMMISSION**<br>**NIHR**<br>**TOTAL**|**Project Title**<br>**Value**<br>**Probability %**<br>**Proj. Adj.**<br>**Value**|
|---|---|
||Policy Horizons (US) - Change Initiative<br>£148,350<br>100<br>£148,350|
||Modelling AMR Dx<br>£136,000<br>5<br>£6,800|
||Creating Opportunities to Hear the<br>Patient Voice<br>£100,056<br>35<br>£35,020|
||Sleep bolt-on development<br>£8,216<br>100<br>£8,216|
||Hearing bolt-on in bilateral cochlear<br>implants<br>£2,822<br>100<br>£2,822|
||Cognition bolt-on in stroke in HK<br>£2,813<br>100<br>£2,813|
||Cognition bolt-on Hong Kong<br>£2,254<br>100<br>£2,254|
||DG SANTE framework bid<br>£0<br>15<br>£0|
||Cognition bolt-on qual analysis<br>£0<br>70<br>£0|
||Hearing bolt-on implants Belgium<br>£0<br>20<br>£0|
||Vision bolt-ons in diabetic retinopathy<br>£0<br>20<br>£0|
||2025/400 i4i FAST NeuroSpeechAI<br>£0<br>100<br>£0|
||DG Grow - supply chains and business<br>intelligence services<br>£0<br>10<br>£0|
||Swallowing and communication bolt-on<br>development<br>£0<br>5<br>£0|
||Adult social care research capacity<br>£0<br>5<br>£0|
||EU HORIZON Green Healthcare<br>£0<br>5<br>£0|
||HEAT-CARE<br>£0<br>5<br>£0<br>£2,196,263<br>£466,518|



## **Unsuccessful proposals, 2025** 

|**FUNDER**<br>**NATIONAL INSTITUTE FOR HEALTH**<br>**RESEARCH (NIHR)**<br>**WELLCOME TRUST**<br>**NATIONAL INSTITUTE FOR HEALTH**<br>**RESEARCH (NIHR)**<br>**SCIENCE FOR AFRICA**<br>**WELLCOME TRUST**<br>**UKRI**<br>**NATIONAL INSTITUTE FOR HEALTH**<br>**RESEARCH (NIHR)**|**Project Title**<br>**Theme**<br>**Value**|
|---|---|
||NIHR Global LMICs Partnership AMPATH<br>POIHS<br>£494,213|
||AIIG Climate Impact Award<br>POIHS<br>£485,438|
||NIHR Global LMICs Partnership AIIG<br>POIHS<br>£477,750|
||EPSILON<br>POIHS<br>£299,000|
||Climate Impact Award<br>POIHS<br>£250,000|
||Decarbonising H&SC - Scottish Consortium<br>POIHS<br>£190,000|
||NIHR C2-Ai<br>POIHS<br>£175,350|




**----- Start of picture text -----**<br>
60<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

|**FUNDER**<br>**PHYSICIANS COMMITTEE FOR**<br>**RESPONSIBLE MEDICINE**<br>**NATIONAL INSTITUTE FOR HEALTH**<br>**RESEARCH (NIHR)**<br>**EUROQOL RESEARCH FOUNDATION**<br>**NATIONAL INSTITUTE FOR HEALTH**<br>**RESEARCH (NIHR)**<br>**ASTELLAS PHARMA US INC**<br>**TOTAL**|**Project Title**<br>**Theme**<br>**Value**|
|---|---|
||US impact of vegan diets<br>POIHS<br>£136,821|
||NIHR RfPB - PACT PwP<br>VADM<br>£42,500|
||Communication and swallowing bolt-on<br>development<br>MVO<br>£0|
||NIHR Health Kiosks Evaluation<br>POIHS<br>£0|
||Combination therapies legal frameworks<br>EoI<br>£0<br>£2,551,071|




**----- Start of picture text -----**<br>
61<br>**----- End of picture text -----**<br>


ohe.org 



OFFICE OF HEALTH ECONOMICS **ANNUAL CHARITY REPORT** 

## About us 

With over 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organisation. Every day we work to improve health care through pioneering and innovative research, analysis, and education. 

As a global thought leader and publisher in the economics of health, health care, and life sciences, we partner with Universities, Government, health systems and the pharmaceutical industry to research and respond to global health challenges. 

As a government-recognised Independent Research Organisation and not-for-profit, our international reputation for the quality and independence of our research is at the forefront of all we do. OHE provides independent and pioneering resources, research and analyses in health economics, health policy and health statistics. Our work informs decision-making about health care and pharmaceutical issues at a global level. 

All of our work is available for free online at www.ohe.org . 


## ohe.org 

**The Office of Health Economics** A Company Limited by Guarantee of Registered No.09848965 **OHE Consulting** Ltd Registered Company No.09853113 **OHE is a Charity** Registration No.1170829 ohe.org **Registered Office** 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB 

62 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**Registered number: 09848965 Charity number: 1170829** 

## **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS** 

**FOR THE YEAR ENDED 31 DECEMBER 2025** 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Trustees**|Ms A R Charlesworth, Trustee|
|---|---|
||Dr R D Torbett, Trustee|
||Mr W P Holmes, Trustee|
||Mr W B F Brouwer, Trustee|
||Mr P Catchpole, Trustee (resigned 13 November 2025)|
||Mr T E Allvin, Trustee|
||Ms R Tarricone, Trustee (appointed 20 May 2025)|
||Ms V Jordan, Trustee (appointed 1 December 2025)|
|**Company registered**<br>**number**<br>09848965<br>**Charity registered**<br>**number**<br>1170829<br>**Registered office**<br>2nd Floor Goldings House<br>Hay's Galleria<br>2 Hay's Lane<br>London<br>SE1 2HB<br>**Company secretary**<br>R Hollingsworth<br>**Chief executive officer**<br>Prof G Cookson<br>**Independent auditor**<br>BDO LLP<br>55 Baker Street<br>London<br>United Kingdom<br>W1U 7EU<br>**Bankers**<br>National Westminster Bank Plc<br>PO Box 414<br>38 Strand<br>London<br>WC2H 5JB||





Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

|**CONTENTS**||
|---|---|
||Page|
|**Trustees' Report**|1 - 7|
|**Independent Auditor's Report**|8 - 13|
|**Consolidated Statement of Financial Activities**|14|
|**Consolidated Balance Sheet**|15|
|**Company Balance Sheet**|16 - 17|
|**Consolidated Statement of Cash Flows**|18|
|**Notes to the Financial Statements**|19 - 32|





Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2025** 

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, ‘The Office of Health Economics’ ("OHE", "the charitable company", "the charity" or "the company") (charity number 1170829) (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2025. 

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019. 

As stated in Note 19 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The registered address of the ABPI is 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below. 

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019 ("Charities SORP FRS 102"). 

## **Objectives and activities** 

The Office of Health Economics’ objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy. 

Activities in furtherance of this include, in particular, but not exclusively: 

- the promotion of evidence based health care policy, by carrying out research on the economics of 

- health, health care systems and the life sciences industry; 

- the promotion of effective and efficient use of health care resources, by advancing the use of 

- economic approaches to support decision making; and 

- the facilitation of decision making and awareness of health care policy issues, by encouraging 

- debate and dissemination of relevant health economics research. 

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care. 

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public. 

Page 1 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Achievements and performance** 

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE’s work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic activities. OHE’s consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity. 

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI. 

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2025, research funding was 105% of target and consultancy income was 115% of target.Consultancy income grew 5% compared to the previous year whilst research funding grew 18%. Operating expenditure in 2025 was 103% of the budget target. Overall, the company made a net operating loss, before receipt of Gift Aid from OHE Consulting Limited, as it made significant investments in charitable work. However, overall the group reported a strong surplus of more than 340% of target which has enabled it to reach its reserves target. 

## **Financial review** 

## **a. Going concern** 

After making appropriate enquiries, and getting confirmation of on going support from ABPI (Note 18), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. 

The Trustees are aware that the operational and financial implications of the various conflict in the world, have been considered by the Governance Committee of OHE’s ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. 

Page 2 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Financial review (continued)** 

## **b. Reserves policy** 

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources. 

The group’s reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The charity reserves were £2,024,129 _(2024 - £1,567,558_ ) as at the year ended 31 December 2025. 

The group's reserves target is 6 months of payroll expenditure. For 2026, that would be a target of £1,994,802 which has now been met. The Trustees and Executive Management will review the Reserves Policy this year whilst continuing to target a 5% surplus. We suggest that generating a surplus which is too significant would not be in accordance with delivering on our Charitable Objects. 

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not-for-profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments. 

## **c. Work programmes and funding** 

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, as well as government agencies, European Commission, and a number of charitable and other organisations. 

## **d. Results for the year** 

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £1,119,472 _(2024 - £1,614,938)_ and made a qualifying charitable donation via Gift Aid for this amount to its parent company, the OHE. 

The company made an operating loss of £662,901 _(2024 - £1,194,790)_ prior to the Gift Aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2025 of £456,571 _(2024 - profit of £474,894)_ . 

## **e. Fundraising** 

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fundraising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants. 

Page 3 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Structure, governance and management** 

## **a. Constitution and legal structure** 

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015. 

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel. 

## **b. Methods of appointment or election of Trustees** 

The management of the company is the responsibility of the Trustees who are elected and co opted under the terms of the Memorandum of Association. 

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity. 

## **c. Policies adopted for the induction and training of Trustees** 

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets. 

## **d. Pay policy for key management personnel** 

Two Trustees _(2024: Two)_ received fees for services during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements. 

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends. 

Page 4 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

**TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

**Structure, governance and management (continued)** 

## **e. Organisational structure and decision-making policies** 

The company is governed by the Board of Trustees. The Trustees of the company during the period were as follows: 

Ms A Charlesworth, Trustee Mr R D Torbett, Trustee Mr W P Holmes, Trustee Mr W B F Brouwer, Trustee Mr P Catchpole, Trustee (resigned 13 November 2025) Mr T E Allvin, Trustee Ms R Tarricone, Trustee (appointed 20 May 2025) Ms V Jordan, Trustee (appointed 1 December 2025) 

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by an Editorial Committee, a Research Committee and a Policy Committee. Each Committee is Chaired by a Trustee and provides regular reports to the entire Board. 

The Executive Management Team during the period were as follows: 

Prof G Cookson (Chief Executive) Prof L Steuten (Deputy Chief Executive) Prof M Jofre Bonet (Chief Research Officer and Head of Education) 

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. Transactions with other related parties are disclosed in Note 18. 

As per the company Articles, the ABPI is entitled to appoint a majority of the Trustees (4/7), one of which is the Chief Executive of the ABPI. 

## **f. Risk management** 

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks. They have also considered the reputational risk of the company and ensure transparency and strong communiaction is carried out with stakeholders. 

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff. 

Page 5 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Plans for future periods** 

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as an established charity, OHE will be developing evidence based policy positions, which it will disseminate by engaging with a wide range of stakeholders via events, media commentaries, and publications. 

## **Statement of Trustees' responsibilities** 

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles of the Charities SORP (FRS 102); 

- make judgements and accounting estimates that are reasonable and prudent; 

- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements; and 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business. 

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

## **Disclosure of information to auditor** 

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that: 

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditor is unaware; and 

- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditor is aware of that information. 

Page 6 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Auditor** 

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). The registered office is 55 Baker Street, London, W1U 7EU. 

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies. 

This report was approved by the Trustees, and signed on their behalf by: 


**Trustee** 


**Trustee** 

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST 

Page 7 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS** 

## **Opinion** 

In our opinion the financial statements: 

- give a true and fair view of the state of the Group’s and of the Parent Charitable Company’s affairs as at 31 December 2025 and of the Group’s incoming resources and application of resources for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006. 

We have audited the financial statements of the Office of Health Economics (“the Parent Charitable Company”) and its subsidiaries (“the Group”) for the year ended 31 December 2025 which comprise the following: 

- Consolidated statement of financial activities (incorporating income and expenditure account) 

- Consolidated balance sheet 

- Company balance sheet 

- Consolidated statement of cash flows 

- Notes 1 to 21 to the financial statements 

- A summary of significant accounting policies. 

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 _The Financial Reporting Standard applicable in the UK and Republic of Ireland_ (United Kingdom Generally Accepted Accounting Practice). 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## _Independence_ 

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. 

Page 8 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Group and the Parent Charitable Company’s ability to continue as a going concern. 

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report and Financial Statements, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

Page 9 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Other Companies Act 2006 reporting** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the Trustees’ Report, which includes the Directors’ Report and the Strategic report prepared for the purposes of Company Law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the Strategic report and the Directors’ Report, which are included in the Trustees’ Report, have been prepared in accordance with applicable legal requirements. 

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report. 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion; 

- adequate accounting records have not been kept by the Parent Charitable Company, or returns adequate for our audit have not been received from branches not visited by us; or 

- the Parent Charitable Company financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of Directors’ remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit; or 

- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the directors’ report and from the requirement to prepare a strategic report. 

## **Responsibilities of Trustees** 

As explained more fully in the Statement of Trustees’ responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the Parent Charitable Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so. 

Page 10 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Auditor's responsibilities for the audit of the financial statements** 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the Charitable Company and management. 

## _Extent to which the audit was capable of detecting irregularities, including fraud_ 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: 

_Non-compliance with laws and regulations_ 

## Based on: 

- Our understanding of the Group and the sector in which it operates; 

- Discussion with management and those charged with governance; and 

- Obtaining and understanding of the Group's policies and procedures regarding compliance with laws and regulations 

we considered the significant laws and regulations to be the applicable accounting framework (UK GAAP), Companies Act 2006, Charities Act 2011, and relevant UK tax legislation. 

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be employment law, data protection and health and safety legislation. 

Our procedures in respect of the above included: 

- Enquires of management whether there were any litigations and claims; 

- Enquires of the legal team of the Group and Charitable Company; 

- Review of minutes of meetings of those charged with governance for any instances of non-compliance with laws and regulations; 

- Review of financial statement disclosures and agreeing to supporting documentation; and 

- Review of legal expenditure accounts to understand the nature of expenditure incurred. 

Page 11 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## Fraud 

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included: 

- Enquiry with management and those charged with governance regarding any known or suspected instances of fraud; 

- Obtaining an understanding of the Group’s policies and procedures relating to: 

   - Detecting and responding to the risks of fraud; and 

   - Internal controls established to mitigate risks related to fraud. 

- Review of minutes of meeting of those charged with governance for any known or suspected instances of fraud; 

- Discussion amongst the engagement team as to how and where fraud might occur in the financial statements; and 

- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud; 

Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of controls through the posting of inappropriate journal entries and early consultancy and research revenue recognition. 

Our procedures in respect of the above included: 

- Testing a sample of journal entries throughout the year, which met a defined risk criteria, by agreeing to supporting documentation; 

- Testing an additional unpredictable sample of journals throughout the year, outside of the defined riskcriteria, by agreeing to supporting documentation; and 

- Testing of consulting and research revenue, particularly amounts recognised around the year end. 

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members who were all deemed to have appropriate competence and capabilities and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit. 

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it. 

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. 

Page 12 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Use of our report** 

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company’s members as a body, for our audit work, for this report, or for the opinions we have formed. 


## **Fiona Condron (Statutory Auditor)** 

For and on behalf of BDO LLP, Statutory Auditor London, UK 

Date: 29 September 2026 

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). 

Page 13 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Note**<br>**Income from:**<br>Donations and research grant<br>Charitable activities<br>Other trading activities<br>Interest receivable<br>**Total income**<br>**Expenditure on:**<br>Costs of other trading activities<br>4<br>Charitable activities<br>4<br>**Total expenditure**<br>**Net movement in funds**<br>**Reconciliation of funds:**<br>Total funds brought forward<br>Net movement in funds<br>**Total funds carried forward**|**Unrestricted**<br>**funds**<br>**2025**<br>**£**<br>**302,317**<br>**948,358**<br>**4,414,549**<br>**22,849**<br>**5,688,073**<br>**3,312,806**<br>**1,918,696**<br>**5,231,502**<br>**456,571**<br>**1,567,558**<br>**456,571**<br>**2,024,129**|**Total**<br>**funds**<br>**2025**<br>**£**<br>**302,317**<br>**948,358**<br>**4,414,549**<br>**22,849**<br>**5,688,073**<br>**3,312,806**<br>**1,918,696**<br>**5,231,502**<br>**456,571**<br>**1,567,558**<br>**456,571**<br>**2,024,129**|_Total_<br>_funds_<br>_2024_<br>_£_<br>_205,484_<br>_855,987_<br>_4,204,016_<br>_16,745_|
|---|---|---|---|
||||_5,282,232_|
||||_2,609,887_<br>_2,197,451_|
||||_4,807,338_|
||||_474,894_|
||||_1,092,664_<br>_474,894_|
||||_1,567,558_|



The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. 

The notes on pages 19 to 32 form part of these financial statements. 

Page 14 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965** 

## **CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2025** 

|**Note**<br>**Fixed assets**<br>Tangible assets<br>9<br>**Current assets**<br>Debtors<br>10<br>Cash at bank and in hand<br>Creditors: amounts falling due within one<br>year<br>11<br>**Net current assets**<br>**Total assets less current liabilities**<br>Provisions for liabilities<br>**Net assets**<br>**Total net assets**<br>**Charity funds**<br>Restricted funds<br>Unrestricted funds<br>**Total funds**|**2,358,498**<br>**3,344,965**<br>**5,703,463**<br>**(3,478,659)**|**2025**<br>**£**<br>**1,325**<br>**1,325**<br>**2,224,804**<br>**2,226,129**<br>**(202,000)**<br>**2,024,129**<br>**2,024,129**<br>**-**<br>**2,024,129**<br>**2,024,129**|_2,724,920_<br>_694,601_<br>_3,419,521_<br>_(1,869,183)_|_2024_<br>_£_<br>_17,220_|
|---|---|---|---|---|
|||||_17,220_<br>_1,550,338_|
|||||_1,567,558_<br>_-_|
|||||_1,567,558_|
||||||
|||||_1,567,558_|
|||||_-_<br>_1,567,558_|
||||||
|||||_1,567,558_|



The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements. 

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: 



**Trustee Trustee** 

Date: 29-Sep-2026 | 14:07 BST 

Date: 29-Sep-2026 | 13:23 BST 

The notes on pages 19 to 32 form part of these financial statements. 

Page 15 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965** 

## **COMPANY BALANCE SHEET AS AT 31 DECEMBER 2025** 

|**Note**<br>**Fixed assets**<br>Tangible assets<br>9<br>Investments<br>**Current assets**<br>Debtors<br>10<br>Cash at bank and in hand<br>Creditors: amounts falling due within one<br>year<br>11<br>**Net current assets**<br>**Total net assets less current liabilities**<br>**Charity funds**<br>Unrestricted funds<br>**Total funds**|**3,042,734**<br>**1,122,611**<br>**4,165,345**<br>**(2,142,542)**|**2025**<br>**£**<br>**1,325**<br>**1**<br>**1,326**<br>**2,022,803**<br>**2,024,129**<br>**2,024,129**<br>**2,024,129**|_2,067,875_<br>_305,491_<br>_2,373,366_<br>_(823,029)_|_2024_<br>_£_<br>_17,220_<br>_1_|
|---|---|---|---|---|
|||||_17,221_<br>_1,550,337_|
||||||
|||||_1,567,558_|
|||||_1,567,558_|
||||||
|||||_1,567,558_|



Page 16 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965** 

# **COMPANY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025** 

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements. 

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. 

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements. 

The profit after tax after gift aid of the parent Company for the year was £456,571 _(2024 - £474,894)_ . 

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: 



# **Trustee Trustee** 

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST 

The notes on pages 19 to 32 form part of these financial statements. 

Page 17 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS** 

## **(A Company Limited by Guarantee)** 

## **CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Cash flows from operating activities**<br>Net cash generated from operating activities (note 14)<br>**Cash flows from investing activities**<br>**Net cash provided by investing activities**<br>**Cash flows from financing activities**<br>Interest received<br>**Net cash provided by financing activities**<br>**Change in cash and cash equivalents in the year**<br>Cash and cash equivalents at the beginning of the year<br>**Cash and cash equivalents at the end of the year**<br>The notes on pages 19 to 32 form part of these financial statements|**2025**<br>**£**<br>**2,627,515**<br>**-**<br>**22,849**<br>**22,849**<br>**2,650,364**<br>**694,601**<br>**3,344,965**|_2024_<br>_£_<br>_18,463_|
|---|---|---|
||||
|||_-_|
|||_16,745_|
|||_16,745_|
|||_35,208_<br>_659,393_|
||||
|||_694,601_|
||||



Page 18 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies** 

## **1.1 Basis of preparation of financial statements** 

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. 

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. 

The Statement of Financial Activities (SOFA) and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis. 

The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements. 

The net income and expenditure for the period dealt with in the accounts of the parent company, after receipt of gift aid, was a net income of £456,571 _(2024 - £474,894)_ . 

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered the ongoing support from the ABPI, the evaluation of the conflicts around the world, inflation and interest rate rises, and concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. The ABPI has confrmed its support and provided a letter confirming this. 

There is no indication that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. We have come to this conclusion following a review of the liabilities and cash flow over the next 12-18 months from the date of approval of the accounts. 

## **1.2 Company Status** 

The company is a company limited by guarantee. The members of the company are the Trustees named on page 5. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company. 

## **1.3 Fund accounting** 

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes. 

Page 19 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies (continued)** 

## **1.4 Income** 

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. 

Consultancy and research project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Deferred Income) to the extent that these have not been earned in the period. Project income yet to be invoiced has been accrued within Debtors (Accrued Income). 

## **1.5 Expenditure** 

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. 

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs. 

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements. 

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. 

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities. 

## **1.6 Tangible fixed assets and depreciation** 

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost. 

Page 20 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

# **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies (continued)** 

## **1.6 Tangible fixed assets and depreciation (continued)** 

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method. 

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases: 

IT Software 

- 

33% straight line 

## **1.7 Debtors** 

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. 

## **1.8 Cash and Cash Equivalents** 

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. 

## **1.9 Liabilities** 

Liabilities and provisions are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. 

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. 

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges. 

## **1.10 Financial instruments** 

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. 

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method. 

Page 21 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies (continued)** 

## **1.11 Foreign currencies** 

The company's and group's functional and presentational currency is Pounds Sterling. 

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date. 

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. 

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account. 

## **1.12 Pensions** 

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year. 

## **2. Critical accounting estimates and areas of judgment** 

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. 

Critical accounting estimates and assumptions: 

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. 

Critical areas of judgement: 

## _(a) Impairment of trade and other debtors_ 

The company makes a judgement of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 10 for the net carrying amount of debtors. 

## _(b) Accrued and deferred income_ 

The group reviews the amount of any income generated but not invoiced to customers at the year end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end. 

Page 22 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **3. Analysis of expenditure by activities** 

|Unrestricted<br>Direct charitable expenditure<br>Support costs - governance<br>Support costs - general<br>**Total 2025**<br>Unrestricted<br>Direct charitable expenditure<br>Support costs - governance<br>Support costs - general<br>_Total 2024_|**Activities**<br>**undertaken**<br>**directly**<br>**2025**<br>**£**<br>**1,803,241**<br>**-**<br>**-**<br>**1,803,241**<br>_Activities_<br>_undertaken_<br>_directly_<br>_2024_<br>_£_<br>_1,989,101_<br>_-_<br>_-_<br>_1,989,101_|**Support**<br>**costs**<br>**2025**<br>**£**<br>**-**<br>**32,088**<br>**83,367**<br>**115,455**<br>_Support_<br>_costs_<br>_2024_<br>_£_<br>_-_<br>_114,027_<br>_94,323_<br>_208,350_|**Total**<br>**funds**<br>**2025**<br>**£**<br>**1,803,241**<br>**32,088**<br>**83,367**|
|---|---|---|---|
||||**1,918,696**|
||||_Total_<br>_funds_<br>_2024_<br>_£_<br>_1,989,101_<br>_114,027_<br>_94,323_|
||||_2,197,451_|



Included within Direct charitable expenditure are staff costs totalling £1,017,941 ( _2024 - £1,225,077_ ). A further £2,547,864 ( _2024 - £2,145,635_ ) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £3,565,805 ( _2024 - £3,370,712_ ), is provided in Note 6. 

Page 23 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **3. Analysis of expenditure by activities (continued)** 

## **Analysis of support costs** 

|Legal and professional related costs<br>Accountancy related costs<br>Human resources related costs<br>Facilities related costs<br>IT related costs<br>Other office support related costs<br>**Total 2025**<br>Legal and professional related costs<br>Accountancy related costs<br>Human resources related costs<br>Facilities related costs<br>IT related costs<br>Other office support related costs<br>_Total 2024_|**Governance**<br>**2025**<br>**£**<br>**6,329**<br>**25,759**<br>**-**<br>**-**<br>**-**<br>**-**<br>**32,088**<br>_Governance_<br>_2024_<br>_£_<br>_84,554_<br>_29,473_<br>_-_<br>_-_<br>_-_<br>_-_<br>_114,027_|**General**<br>**2025**<br>**£**<br>**-**<br>**-**<br>**28,025**<br>**1,260**<br>**19,473**<br>**34,609**<br>**83,367**<br>_General_<br>_2024_<br>_£_<br>_-_<br>_-_<br>_26,582_<br>_3,767_<br>_21,035_<br>_42,939_<br>_94,323_|**Total**<br>**funds**<br>**2025**<br>**£**<br>**6,329**<br>**25,759**<br>**28,025**<br>**1,260**<br>**19,473**<br>**34,609**|
|---|---|---|---|
||||**115,455**|
||||_Total_<br>_funds_<br>_2024_<br>_£_<br>_84,554_<br>_29,473_<br>_26,582_<br>_3,767_<br>_21,035_<br>_42,939_|
||||_208,350_|



Page 24 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **4. Analysis of expenditure by expenditure type** 

|**5.**||**Other costs**<br>**2025**|_Other costs_<br>_2024_|
|---|---|---|---|
||**OHE Consulting trading activities**|**£**<br>**3,312,806**|_£_<br>_2,609,887_|
||Direct charitable expenditure|**1,803,241**|_1,989,101_|
||General support costs|**83,367**|_94,323_|
||**Charitable activities**|**1,886,608**|_2,083,424_|
|||||
||**Expenditure on governance**|**32,088**|_114,027_|
|||**1,918,696**|_2,197,451_|
||**Total Expenditure**|**5,231,502**|_4,807,338_|
||**Auditor's remuneration**<br>Fees payable to the company's auditor and its associates in respect of:<br>Audit-related assurance services|**2025**<br>**£**<br>**10,000**|_2024_<br>_£_<br>_10,000_|



## **6. Staff costs** 

Staff costs, including key management personnel (see Note 7), were as follows: 

|Wages and salaries<br>Social security costs<br>Contributions to defined contribution pension<br>schemes (Note 16)|**Group**<br>**2025**<br>**£**<br>**2,982,021**<br>**390,956**<br>**192,828**<br>**3,565,805**|_Group_<br>_2024_<br>_£_<br>_2,845,429_<br>_332,758_<br>_192,525_<br>_3,370,712_|**Company**<br>**2025**<br>**£**<br>**847,191**<br>**112,851**<br>**57,899**<br>**1,017,941**|_Company_<br>_2024_<br>_£_<br>_1,034,880_<br>_129,120_<br>_61,077_|
|---|---|---|---|---|
|||||_1,225,077_|



Page 25 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **6. Staff costs (continued)** 

The average number of persons employed by the company during the year was as follows: 

|Key management personnel<br>Administrative staff|**Group**<br>**2025**<br>**No.**<br>**3**<br>**35**<br>**38**|_Group_<br>_2024_<br>_No._<br>_3_<br>_33_<br>_36_|**Company**<br>**2025**<br>**No.**<br>**3**<br>**35**<br>**38**|_Company_<br>_2024_<br>_No._<br>_3_<br>_33_|
|---|---|---|---|---|
||||||
|||||_36_|



The number of higher paid employees was: 

||**Group**|_Group_|
|---|---|---|
||**2025**|_2024_|
||**No.**|_No._|
|£60,001 - £70,000|**3**|_2_|
|£70,001 - £80,000|**2**|_3_|
|£80,001 - £90,000|**3**|_4_|
|£90,001 - £100,000|**2**|_3_|
|£100,001 - £110,000|**1**|_1_|
|£110,001 - £120,000|**2**|_1_|
|£120,001 - £130,000|**-**|_1_|
|£130,001 - £140,000|**1**|_-_|
|£140,001 - £150,000|**-**|_1_|
|£160,001 - £170,000|**1**|_1_|
|£240,001 - £250,000|**1**|_1_|
|£350,001 - £360,000|**-**|_1_|
|£380,001 - £390,000|**1**|_-_|



The total cost that is reflected in the above bandings is made up of wages and salaries, social security costs and defined contribution pension scheme contributions. 

Page 26 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **7. Key management personnel** 

|Wages and salaries<br>Social security costs<br>Cost of defined contribution scheme (Note 16)|**2025**<br>**£**<br>**797,971**<br>**119,696**<br>**28,303**<br>**945,970**|_2024_<br>_£_<br>_771,027_<br>_106,402_<br>_19,721_|
|---|---|---|
|||_897,150_|



In addition to the Board of Trustees, there were 3 ( _2024 - 3_ ) key management personnel, 2 ( _2024 - 2_ ) of which accrued benefits under another group entity's defined contribution pension scheme during the period. 

## **8. Trustees' fees** 

|Fees for services provided (see below)<br>Reimbursed travel expenses paid to 1 trustee|**2025**<br>**£**<br>**21,398**<br>**-**<br>**21,398**|_2024_<br>_£_<br>_26,470_<br>_269_|
|---|---|---|
|||_26,739_|



The highest paid Trustee received remuneration of £NIL ( _2024 - £NIL_ ). 

A Charlesworth, Trustee, received fees for services provided during the period of £14,398 ( _2024 - £13,606_ ). 

R Tarricone, Trustee, received fees for services provided during the period of £7,000 _(2024 - £NIL)_ . 

M Kyle, Trustee, received fees for services provided during the period of £NIL _(2024 - £12,864)_ . 

The fees paid to the two Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its' objectives. 

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party. 

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period. 

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association. 

Page 27 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **9. Tangible fixed assets** 

## **Group and Company** 

|**Cost or valuation**<br>At 1 January 2025<br>At 31 December 2025<br>**Depreciation**<br>At 1 January 2025<br>Charge for the year<br>At 31 December 2025<br>**Net book value**<br>At 31 December 2025<br>_At 31 December 2024_|**IT software**<br>**£**<br>**47,685**|
|---|---|
||**47,685**|
||**30,465**<br>**15,895**|
||**46,360**|
||**1,325**|
||_17,220_|



## **10. Debtors** 

|**Due within one year**<br>Trade debtors<br>Amounts owed by group undertakings<br>Other debtors<br>Prepayments and accrued income|**Group**<br>**2025**<br>**£**<br>**1,456,008**<br>**-**<br>**7,238**<br>**895,252**<br>**2,358,498**|_Group_<br>_2024_<br>_£_<br>_2,010,319_<br>_-_<br>_54,249_<br>_660,352_<br>_2,724,920_|**Company**<br>**2025**<br>**£**<br>**164,753**<br>**2,415,112**<br>**7,238**<br>**455,631**<br>**3,042,734**|_Company_<br>_2024_<br>_£_<br>_185,788_<br>_1,597,341_<br>_54,249_<br>_230,497_<br>_2,067,875_|
|---|---|---|---|---|



Page 28 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **11. Creditors: Amounts falling due within one year** 

|Trade creditors<br>Amounts owed to ultimate parent<br>Other taxation and social security<br>Other creditors<br>Accruals and deferred income<br>Deferred income at the beginning of the year<br>Resources deferred during the year<br>Amounts released from previous periods<br>**Deferred income at the end of the year**<br>**Financial instruments**<br>**Financial assets**<br>Financial assets measured at fair value<br>through income and expenditure<br>Financial assets measured at amortised cost<br>**Financial liabilities**<br>Financial liabilities measured at cost less<br>impairment|**Group**<br>**2025**<br>**£**<br>**44,024**<br>**1,684,993**<br>**4,346**<br>**3,047**<br>**1,742,249**<br>**3,478,659**<br>**Group**<br>**2025**<br>**£**<br>**880,844**<br>**1,389,267**<br>**(880,844)**<br>**1,389,267**<br>**Group**<br>**2025**<br>**£**<br>**3,344,965**<br>**2,329,146**<br>**5,674,111**<br>**Group**<br>**2025**<br>**£**<br>**2,291,392**|_Group_<br>_2024_<br>_£_<br>_61,287_<br>_578,890_<br>_4,678_<br>_43,000_<br>_1,181,328_<br>_1,869,183_<br>_Group_<br>_2024_<br>_£_<br>_581,655_<br>_880,844_<br>_(581,655)_<br>_880,844_<br>_Group_<br>_2024_<br>_£_<br>_694,601_<br>_2,012,754_<br>_2,707,355_<br>_Group_<br>_2024_<br>_£_<br>_988,339_|**Company**<br>**2025**<br>**£**<br>**27,432**<br>**1,623,249**<br>**4,346**<br>**3,047**<br>**484,468**<br>**2,142,542**<br>**Company**<br>**2025**<br>**£**<br>**111,904**<br>**337,687**<br>**(111,904)**<br>**337,687**<br>**Company**<br>**2025**<br>**£**<br>**1,122,611**<br>**3,013,381**<br>**4,135,992**<br>**Company**<br>**2025**<br>**£**<br>**1,804,854**|_Company_<br>_2024_<br>_£_<br>_47,657_<br>_517,369_<br>_4,678_<br>_2,310_<br>_251,015_<br>_823,029_<br>_Company_<br>_2024_<br>_£_<br>_57,369_<br>_111,904_<br>_(57,369)_<br>_111,904_<br>_Company_<br>_2024_<br>_£_<br>_305,491_<br>_1,785,564_<br>_2,091,055_<br>_Company_<br>_2024_<br>_£_<br>_711,125_|
|---|---|---|---|---|



## **12. Financial instruments** 

Page 29 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **12. Financial instruments (continued)** 

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents. 

Financial assets measured at amortised cost compromise of debtors falling due within one year, excluding prepayments. 

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income. 

## **13. Provisions** 

## **Group** 

|Additions|**Provisions**<br>**£**<br>**202,000**|
|---|---|
|||
||**202,000**|



Included within the provisions balance at the year end is an amount for ongoing legal related matters. 

## **14. Reconciliation of net movement in funds to net cash flow provided by operating activities** 

|Net surplus for the year (as per Statement of Financial Activities)<br>**Adjustments for:**<br>Depreciation charges<br>Decrease/(Increase) in debtors<br>Increase in creditors<br>Interest received<br>**Net cash provided by operating activities**|**Group**<br>**2025**<br>**£**<br>**456,571**<br>**15,895**<br>**366,422**<br>**1,811,476**<br>**(22,849)**<br>**2,627,515**|_Group_<br>_2024_<br>_£_<br>_474,894_|
|---|---|---|
|||_15,895_<br>_(845,541)_<br>_389,960_<br>_(16,745)_|
||||
|||_18,463_|



Page 30 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **15. Cash and cash equivalents** 

|Cash at bank and in hand<br>**Total cash and cash equivalents**|**Group**<br>**2025**<br>**£**<br>**3,344,965**<br>**3,344,965**|_Group_<br>_2024_<br>_£_<br>_694,601_|
|---|---|---|
||||
|||_694,601_|



## **16. Analysis of changes in net debt (Group)** 

|Cash at bank and in hand|**At 1**<br>**January**<br>**2025**<br>**£**<br>**694,601**<br>**694,601**|**Cash flows**<br>**£**<br>**2,650,364**<br>**2,650,364**|**At 31**<br>**December**<br>**2025**<br>**£**<br>**3,344,965**|
|---|---|---|---|
||||**3,344,965**|



## **17. Pension commitments** 

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable to the fund, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £192,828 _(2024 - £192,525)_ for the group and £57,899 ( _2024 - £61,077_ ) for the company. 

## **18. Related party transactions** 

During the period two Trustees received fees for services totalling £21,398 ( _2024 - £26,470_ ) (refer to Note 8 for details). At the balance sheet date, no amount ( _2024 - £Nil_ ) of this was outstanding. 

During the period the company received research grants totalling £100,000 ( _2024 - £150,000_ ) from the ABPI. 

During the period, the group and company incurred support costs totalling £395,592 and £115,456 respectively ( _2024 - £443,280 and £208,350_ ), which were recharged by the ABPI (refer to Note 19 below). 

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred as a qualifying charitable donation via Gift Aid (refer to Note 20 below). 

Page 31 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **19. Ultimate parent undertaking and controlling party** 

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. 

## **20. Principal subsidiaries** 

The following was a subsidiary undertaking of the company: 

|**Name**|**Country of Incorporation**|**Principal activity**|**Holding**|
|---|---|---|---|
|OHE Consulting Limited|United Kingdom|Provision of policy and|**100%**|
|||strategic expertise on||
|||healthcare and related||
|||matters.||



During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £4,414,549 ( _2024 - £4,204,016_ ), and incurred expenditure totalling £3,312,806 ( _2024 - £2,602,333_ ), plus interest received of £17,729 _(2024 - £13,255_ ), generating profits for the period of £1,119,472 ( _2024 - £1,614,938_ ). OHE Consulting Limited elected to transfer its profits to the company by way of a qualifying charitable donation via Gift Aid, leaving aggregated assets in OHE Consulting Limited of £1 at the period end. 

## **21. Post balance sheet events** 

There have been no significant events affecting the group since the year-end. 

Page 32 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**Registered number: 09848965 Charity number: 1170829** 

## **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS** 

**FOR THE YEAR ENDED 31 DECEMBER 2025** 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Trustees**|Ms A R Charlesworth, Trustee|
|---|---|
||Dr R D Torbett, Trustee|
||Mr W P Holmes, Trustee|
||Mr W B F Brouwer, Trustee|
||Mr P Catchpole, Trustee (resigned 13 November 2025)|
||Mr T E Allvin, Trustee|
||Ms R Tarricone, Trustee (appointed 20 May 2025)|
||Ms V Jordan, Trustee (appointed 1 December 2025)|
|**Company registered**<br>**number**<br>09848965<br>**Charity registered**<br>**number**<br>1170829<br>**Registered office**<br>2nd Floor Goldings House<br>Hay's Galleria<br>2 Hay's Lane<br>London<br>SE1 2HB<br>**Company secretary**<br>R Hollingsworth<br>**Chief executive officer**<br>Prof G Cookson<br>**Independent auditor**<br>BDO LLP<br>55 Baker Street<br>London<br>United Kingdom<br>W1U 7EU<br>**Bankers**<br>National Westminster Bank Plc<br>PO Box 414<br>38 Strand<br>London<br>WC2H 5JB||





Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

|**CONTENTS**||
|---|---|
||Page|
|**Trustees' Report**|1 - 7|
|**Independent Auditor's Report**|8 - 13|
|**Consolidated Statement of Financial Activities**|14|
|**Consolidated Balance Sheet**|15|
|**Company Balance Sheet**|16 - 17|
|**Consolidated Statement of Cash Flows**|18|
|**Notes to the Financial Statements**|19 - 32|





Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2025** 

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, ‘The Office of Health Economics’ ("OHE", "the charitable company", "the charity" or "the company") (charity number 1170829) (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2025. 

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019. 

As stated in Note 19 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The registered address of the ABPI is 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below. 

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019 ("Charities SORP FRS 102"). 

## **Objectives and activities** 

The Office of Health Economics’ objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy. 

Activities in furtherance of this include, in particular, but not exclusively: 

- the promotion of evidence based health care policy, by carrying out research on the economics of 

- health, health care systems and the life sciences industry; 

- the promotion of effective and efficient use of health care resources, by advancing the use of 

- economic approaches to support decision making; and 

- the facilitation of decision making and awareness of health care policy issues, by encouraging 

- debate and dissemination of relevant health economics research. 

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care. 

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public. 

Page 1 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Achievements and performance** 

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE’s work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic activities. OHE’s consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity. 

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI. 

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2025, research funding was 105% of target and consultancy income was 115% of target.Consultancy income grew 5% compared to the previous year whilst research funding grew 18%. Operating expenditure in 2025 was 103% of the budget target. Overall, the company made a net operating loss, before receipt of Gift Aid from OHE Consulting Limited, as it made significant investments in charitable work. However, overall the group reported a strong surplus of more than 340% of target which has enabled it to reach its reserves target. 

## **Financial review** 

## **a. Going concern** 

After making appropriate enquiries, and getting confirmation of on going support from ABPI (Note 18), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. 

The Trustees are aware that the operational and financial implications of the various conflict in the world, have been considered by the Governance Committee of OHE’s ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. 

Page 2 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Financial review (continued)** 

## **b. Reserves policy** 

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources. 

The group’s reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The charity reserves were £2,024,129 _(2024 - £1,567,558_ ) as at the year ended 31 December 2025. 

The group's reserves target is 6 months of payroll expenditure. For 2026, that would be a target of £1,994,802 which has now been met. The Trustees and Executive Management will review the Reserves Policy this year whilst continuing to target a 5% surplus. We suggest that generating a surplus which is too significant would not be in accordance with delivering on our Charitable Objects. 

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not-for-profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments. 

## **c. Work programmes and funding** 

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, as well as government agencies, European Commission, and a number of charitable and other organisations. 

## **d. Results for the year** 

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £1,119,472 _(2024 - £1,614,938)_ and made a qualifying charitable donation via Gift Aid for this amount to its parent company, the OHE. 

The company made an operating loss of £662,901 _(2024 - £1,194,790)_ prior to the Gift Aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2025 of £456,571 _(2024 - profit of £474,894)_ . 

## **e. Fundraising** 

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fundraising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants. 

Page 3 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Structure, governance and management** 

## **a. Constitution and legal structure** 

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015. 

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel. 

## **b. Methods of appointment or election of Trustees** 

The management of the company is the responsibility of the Trustees who are elected and co opted under the terms of the Memorandum of Association. 

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity. 

## **c. Policies adopted for the induction and training of Trustees** 

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets. 

## **d. Pay policy for key management personnel** 

Two Trustees _(2024: Two)_ received fees for services during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements. 

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends. 

Page 4 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

**TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

**Structure, governance and management (continued)** 

## **e. Organisational structure and decision-making policies** 

The company is governed by the Board of Trustees. The Trustees of the company during the period were as follows: 

Ms A Charlesworth, Trustee Mr R D Torbett, Trustee Mr W P Holmes, Trustee Mr W B F Brouwer, Trustee Mr P Catchpole, Trustee (resigned 13 November 2025) Mr T E Allvin, Trustee Ms R Tarricone, Trustee (appointed 20 May 2025) Ms V Jordan, Trustee (appointed 1 December 2025) 

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by an Editorial Committee, a Research Committee and a Policy Committee. Each Committee is Chaired by a Trustee and provides regular reports to the entire Board. 

The Executive Management Team during the period were as follows: 

Prof G Cookson (Chief Executive) Prof L Steuten (Deputy Chief Executive) Prof M Jofre Bonet (Chief Research Officer and Head of Education) 

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. Transactions with other related parties are disclosed in Note 18. 

As per the company Articles, the ABPI is entitled to appoint a majority of the Trustees (4/7), one of which is the Chief Executive of the ABPI. 

## **f. Risk management** 

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks. They have also considered the reputational risk of the company and ensure transparency and strong communiaction is carried out with stakeholders. 

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff. 

Page 5 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Plans for future periods** 

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as an established charity, OHE will be developing evidence based policy positions, which it will disseminate by engaging with a wide range of stakeholders via events, media commentaries, and publications. 

## **Statement of Trustees' responsibilities** 

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles of the Charities SORP (FRS 102); 

- make judgements and accounting estimates that are reasonable and prudent; 

- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements; and 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business. 

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

## **Disclosure of information to auditor** 

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that: 

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditor is unaware; and 

- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditor is aware of that information. 

Page 6 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **Auditor** 

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). The registered office is 55 Baker Street, London, W1U 7EU. 

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies. 

This report was approved by the Trustees, and signed on their behalf by: 


**Trustee** 


**Trustee** 

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST 

Page 7 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS** 

## **Opinion** 

In our opinion the financial statements: 

- give a true and fair view of the state of the Group’s and of the Parent Charitable Company’s affairs as at 31 December 2025 and of the Group’s incoming resources and application of resources for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006. 

We have audited the financial statements of the Office of Health Economics (“the Parent Charitable Company”) and its subsidiaries (“the Group”) for the year ended 31 December 2025 which comprise the following: 

- Consolidated statement of financial activities (incorporating income and expenditure account) 

- Consolidated balance sheet 

- Company balance sheet 

- Consolidated statement of cash flows 

- Notes 1 to 21 to the financial statements 

- A summary of significant accounting policies. 

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 _The Financial Reporting Standard applicable in the UK and Republic of Ireland_ (United Kingdom Generally Accepted Accounting Practice). 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## _Independence_ 

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. 

Page 8 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Group and the Parent Charitable Company’s ability to continue as a going concern. 

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report and Financial Statements, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

Page 9 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Other Companies Act 2006 reporting** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the Trustees’ Report, which includes the Directors’ Report and the Strategic report prepared for the purposes of Company Law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the Strategic report and the Directors’ Report, which are included in the Trustees’ Report, have been prepared in accordance with applicable legal requirements. 

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report. 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion; 

- adequate accounting records have not been kept by the Parent Charitable Company, or returns adequate for our audit have not been received from branches not visited by us; or 

- the Parent Charitable Company financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of Directors’ remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit; or 

- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the directors’ report and from the requirement to prepare a strategic report. 

## **Responsibilities of Trustees** 

As explained more fully in the Statement of Trustees’ responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the Parent Charitable Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so. 

Page 10 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Auditor's responsibilities for the audit of the financial statements** 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the Charitable Company and management. 

## _Extent to which the audit was capable of detecting irregularities, including fraud_ 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: 

_Non-compliance with laws and regulations_ 

## Based on: 

- Our understanding of the Group and the sector in which it operates; 

- Discussion with management and those charged with governance; and 

- Obtaining and understanding of the Group's policies and procedures regarding compliance with laws and regulations 

we considered the significant laws and regulations to be the applicable accounting framework (UK GAAP), Companies Act 2006, Charities Act 2011, and relevant UK tax legislation. 

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be employment law, data protection and health and safety legislation. 

Our procedures in respect of the above included: 

- Enquires of management whether there were any litigations and claims; 

- Enquires of the legal team of the Group and Charitable Company; 

- Review of minutes of meetings of those charged with governance for any instances of non-compliance with laws and regulations; 

- Review of financial statement disclosures and agreeing to supporting documentation; and 

- Review of legal expenditure accounts to understand the nature of expenditure incurred. 

Page 11 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## Fraud 

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included: 

- Enquiry with management and those charged with governance regarding any known or suspected instances of fraud; 

- Obtaining an understanding of the Group’s policies and procedures relating to: 

   - Detecting and responding to the risks of fraud; and 

   - Internal controls established to mitigate risks related to fraud. 

- Review of minutes of meeting of those charged with governance for any known or suspected instances of fraud; 

- Discussion amongst the engagement team as to how and where fraud might occur in the financial statements; and 

- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud; 

Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of controls through the posting of inappropriate journal entries and early consultancy and research revenue recognition. 

Our procedures in respect of the above included: 

- Testing a sample of journal entries throughout the year, which met a defined risk criteria, by agreeing to supporting documentation; 

- Testing an additional unpredictable sample of journals throughout the year, outside of the defined riskcriteria, by agreeing to supporting documentation; and 

- Testing of consulting and research revenue, particularly amounts recognised around the year end. 

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members who were all deemed to have appropriate competence and capabilities and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit. 

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it. 

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. 

Page 12 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  THE OFFICE OF HEALTH ECONOMICS (CONTINUED)** 

## **Use of our report** 

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company’s members as a body, for our audit work, for this report, or for the opinions we have formed. 


## **Fiona Condron (Statutory Auditor)** 

For and on behalf of BDO LLP, Statutory Auditor London, UK 

Date: 29 September 2026 

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). 

Page 13 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Note**<br>**Income from:**<br>Donations and research grant<br>Charitable activities<br>Other trading activities<br>Interest receivable<br>**Total income**<br>**Expenditure on:**<br>Costs of other trading activities<br>4<br>Charitable activities<br>4<br>**Total expenditure**<br>**Net movement in funds**<br>**Reconciliation of funds:**<br>Total funds brought forward<br>Net movement in funds<br>**Total funds carried forward**|**Unrestricted**<br>**funds**<br>**2025**<br>**£**<br>**302,317**<br>**948,358**<br>**4,414,549**<br>**22,849**<br>**5,688,073**<br>**3,312,806**<br>**1,918,696**<br>**5,231,502**<br>**456,571**<br>**1,567,558**<br>**456,571**<br>**2,024,129**|**Total**<br>**funds**<br>**2025**<br>**£**<br>**302,317**<br>**948,358**<br>**4,414,549**<br>**22,849**<br>**5,688,073**<br>**3,312,806**<br>**1,918,696**<br>**5,231,502**<br>**456,571**<br>**1,567,558**<br>**456,571**<br>**2,024,129**|_Total_<br>_funds_<br>_2024_<br>_£_<br>_205,484_<br>_855,987_<br>_4,204,016_<br>_16,745_|
|---|---|---|---|
||||_5,282,232_|
||||_2,609,887_<br>_2,197,451_|
||||_4,807,338_|
||||_474,894_|
||||_1,092,664_<br>_474,894_|
||||_1,567,558_|



The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. 

The notes on pages 19 to 32 form part of these financial statements. 

Page 14 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965** 

## **CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2025** 

|**Note**<br>**Fixed assets**<br>Tangible assets<br>9<br>**Current assets**<br>Debtors<br>10<br>Cash at bank and in hand<br>Creditors: amounts falling due within one<br>year<br>11<br>**Net current assets**<br>**Total assets less current liabilities**<br>Provisions for liabilities<br>**Net assets**<br>**Total net assets**<br>**Charity funds**<br>Restricted funds<br>Unrestricted funds<br>**Total funds**|**2,358,498**<br>**3,344,965**<br>**5,703,463**<br>**(3,478,659)**|**2025**<br>**£**<br>**1,325**<br>**1,325**<br>**2,224,804**<br>**2,226,129**<br>**(202,000)**<br>**2,024,129**<br>**2,024,129**<br>**-**<br>**2,024,129**<br>**2,024,129**|_2,724,920_<br>_694,601_<br>_3,419,521_<br>_(1,869,183)_|_2024_<br>_£_<br>_17,220_|
|---|---|---|---|---|
|||||_17,220_<br>_1,550,338_|
|||||_1,567,558_<br>_-_|
|||||_1,567,558_|
||||||
|||||_1,567,558_|
|||||_-_<br>_1,567,558_|
||||||
|||||_1,567,558_|



The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements. 

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: 



**Trustee Trustee** 

Date: 29-Sep-2026 | 14:07 BST 

Date: 29-Sep-2026 | 13:23 BST 

The notes on pages 19 to 32 form part of these financial statements. 

Page 15 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965** 

## **COMPANY BALANCE SHEET AS AT 31 DECEMBER 2025** 

|**Note**<br>**Fixed assets**<br>Tangible assets<br>9<br>Investments<br>**Current assets**<br>Debtors<br>10<br>Cash at bank and in hand<br>Creditors: amounts falling due within one<br>year<br>11<br>**Net current assets**<br>**Total net assets less current liabilities**<br>**Charity funds**<br>Unrestricted funds<br>**Total funds**|**3,042,734**<br>**1,122,611**<br>**4,165,345**<br>**(2,142,542)**|**2025**<br>**£**<br>**1,325**<br>**1**<br>**1,326**<br>**2,022,803**<br>**2,024,129**<br>**2,024,129**<br>**2,024,129**|_2,067,875_<br>_305,491_<br>_2,373,366_<br>_(823,029)_|_2024_<br>_£_<br>_17,220_<br>_1_|
|---|---|---|---|---|
|||||_17,221_<br>_1,550,337_|
||||||
|||||_1,567,558_|
|||||_1,567,558_|
||||||
|||||_1,567,558_|



Page 16 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965** 

# **COMPANY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025** 

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements. 

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. 

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements. 

The profit after tax after gift aid of the parent Company for the year was £456,571 _(2024 - £474,894)_ . 

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: 



# **Trustee Trustee** 

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST 

The notes on pages 19 to 32 form part of these financial statements. 

Page 17 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS** 

## **(A Company Limited by Guarantee)** 

## **CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025** 

|**Cash flows from operating activities**<br>Net cash generated from operating activities (note 14)<br>**Cash flows from investing activities**<br>**Net cash provided by investing activities**<br>**Cash flows from financing activities**<br>Interest received<br>**Net cash provided by financing activities**<br>**Change in cash and cash equivalents in the year**<br>Cash and cash equivalents at the beginning of the year<br>**Cash and cash equivalents at the end of the year**<br>The notes on pages 19 to 32 form part of these financial statements|**2025**<br>**£**<br>**2,627,515**<br>**-**<br>**22,849**<br>**22,849**<br>**2,650,364**<br>**694,601**<br>**3,344,965**|_2024_<br>_£_<br>_18,463_|
|---|---|---|
||||
|||_-_|
|||_16,745_|
|||_16,745_|
|||_35,208_<br>_659,393_|
||||
|||_694,601_|
||||



Page 18 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS** 

**(A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies** 

## **1.1 Basis of preparation of financial statements** 

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. 

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. 

The Statement of Financial Activities (SOFA) and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis. 

The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements. 

The net income and expenditure for the period dealt with in the accounts of the parent company, after receipt of gift aid, was a net income of £456,571 _(2024 - £474,894)_ . 

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered the ongoing support from the ABPI, the evaluation of the conflicts around the world, inflation and interest rate rises, and concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. The ABPI has confrmed its support and provided a letter confirming this. 

There is no indication that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. We have come to this conclusion following a review of the liabilities and cash flow over the next 12-18 months from the date of approval of the accounts. 

## **1.2 Company Status** 

The company is a company limited by guarantee. The members of the company are the Trustees named on page 5. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company. 

## **1.3 Fund accounting** 

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes. 

Page 19 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies (continued)** 

## **1.4 Income** 

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. 

Consultancy and research project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Deferred Income) to the extent that these have not been earned in the period. Project income yet to be invoiced has been accrued within Debtors (Accrued Income). 

## **1.5 Expenditure** 

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. 

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs. 

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements. 

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. 

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities. 

## **1.6 Tangible fixed assets and depreciation** 

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost. 

Page 20 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

# **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

# **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies (continued)** 

## **1.6 Tangible fixed assets and depreciation (continued)** 

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method. 

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases: 

IT Software 

- 

33% straight line 

## **1.7 Debtors** 

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. 

## **1.8 Cash and Cash Equivalents** 

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. 

## **1.9 Liabilities** 

Liabilities and provisions are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. 

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. 

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges. 

## **1.10 Financial instruments** 

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. 

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method. 

Page 21 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

**THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **1. Accounting policies (continued)** 

## **1.11 Foreign currencies** 

The company's and group's functional and presentational currency is Pounds Sterling. 

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date. 

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. 

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account. 

## **1.12 Pensions** 

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year. 

## **2. Critical accounting estimates and areas of judgment** 

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. 

Critical accounting estimates and assumptions: 

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. 

Critical areas of judgement: 

## _(a) Impairment of trade and other debtors_ 

The company makes a judgement of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 10 for the net carrying amount of debtors. 

## _(b) Accrued and deferred income_ 

The group reviews the amount of any income generated but not invoiced to customers at the year end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end. 

Page 22 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **3. Analysis of expenditure by activities** 

|Unrestricted<br>Direct charitable expenditure<br>Support costs - governance<br>Support costs - general<br>**Total 2025**<br>Unrestricted<br>Direct charitable expenditure<br>Support costs - governance<br>Support costs - general<br>_Total 2024_|**Activities**<br>**undertaken**<br>**directly**<br>**2025**<br>**£**<br>**1,803,241**<br>**-**<br>**-**<br>**1,803,241**<br>_Activities_<br>_undertaken_<br>_directly_<br>_2024_<br>_£_<br>_1,989,101_<br>_-_<br>_-_<br>_1,989,101_|**Support**<br>**costs**<br>**2025**<br>**£**<br>**-**<br>**32,088**<br>**83,367**<br>**115,455**<br>_Support_<br>_costs_<br>_2024_<br>_£_<br>_-_<br>_114,027_<br>_94,323_<br>_208,350_|**Total**<br>**funds**<br>**2025**<br>**£**<br>**1,803,241**<br>**32,088**<br>**83,367**|
|---|---|---|---|
||||**1,918,696**|
||||_Total_<br>_funds_<br>_2024_<br>_£_<br>_1,989,101_<br>_114,027_<br>_94,323_|
||||_2,197,451_|



Included within Direct charitable expenditure are staff costs totalling £1,017,941 ( _2024 - £1,225,077_ ). A further £2,547,864 ( _2024 - £2,145,635_ ) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £3,565,805 ( _2024 - £3,370,712_ ), is provided in Note 6. 

Page 23 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **3. Analysis of expenditure by activities (continued)** 

## **Analysis of support costs** 

|Legal and professional related costs<br>Accountancy related costs<br>Human resources related costs<br>Facilities related costs<br>IT related costs<br>Other office support related costs<br>**Total 2025**<br>Legal and professional related costs<br>Accountancy related costs<br>Human resources related costs<br>Facilities related costs<br>IT related costs<br>Other office support related costs<br>_Total 2024_|**Governance**<br>**2025**<br>**£**<br>**6,329**<br>**25,759**<br>**-**<br>**-**<br>**-**<br>**-**<br>**32,088**<br>_Governance_<br>_2024_<br>_£_<br>_84,554_<br>_29,473_<br>_-_<br>_-_<br>_-_<br>_-_<br>_114,027_|**General**<br>**2025**<br>**£**<br>**-**<br>**-**<br>**28,025**<br>**1,260**<br>**19,473**<br>**34,609**<br>**83,367**<br>_General_<br>_2024_<br>_£_<br>_-_<br>_-_<br>_26,582_<br>_3,767_<br>_21,035_<br>_42,939_<br>_94,323_|**Total**<br>**funds**<br>**2025**<br>**£**<br>**6,329**<br>**25,759**<br>**28,025**<br>**1,260**<br>**19,473**<br>**34,609**|
|---|---|---|---|
||||**115,455**|
||||_Total_<br>_funds_<br>_2024_<br>_£_<br>_84,554_<br>_29,473_<br>_26,582_<br>_3,767_<br>_21,035_<br>_42,939_|
||||_208,350_|



Page 24 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **4. Analysis of expenditure by expenditure type** 

|**5.**||**Other costs**<br>**2025**|_Other costs_<br>_2024_|
|---|---|---|---|
||**OHE Consulting trading activities**|**£**<br>**3,312,806**|_£_<br>_2,609,887_|
||Direct charitable expenditure|**1,803,241**|_1,989,101_|
||General support costs|**83,367**|_94,323_|
||**Charitable activities**|**1,886,608**|_2,083,424_|
|||||
||**Expenditure on governance**|**32,088**|_114,027_|
|||**1,918,696**|_2,197,451_|
||**Total Expenditure**|**5,231,502**|_4,807,338_|
||**Auditor's remuneration**<br>Fees payable to the company's auditor and its associates in respect of:<br>Audit-related assurance services|**2025**<br>**£**<br>**10,000**|_2024_<br>_£_<br>_10,000_|



## **6. Staff costs** 

Staff costs, including key management personnel (see Note 7), were as follows: 

|Wages and salaries<br>Social security costs<br>Contributions to defined contribution pension<br>schemes (Note 16)|**Group**<br>**2025**<br>**£**<br>**2,982,021**<br>**390,956**<br>**192,828**<br>**3,565,805**|_Group_<br>_2024_<br>_£_<br>_2,845,429_<br>_332,758_<br>_192,525_<br>_3,370,712_|**Company**<br>**2025**<br>**£**<br>**847,191**<br>**112,851**<br>**57,899**<br>**1,017,941**|_Company_<br>_2024_<br>_£_<br>_1,034,880_<br>_129,120_<br>_61,077_|
|---|---|---|---|---|
|||||_1,225,077_|



Page 25 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **6. Staff costs (continued)** 

The average number of persons employed by the company during the year was as follows: 

|Key management personnel<br>Administrative staff|**Group**<br>**2025**<br>**No.**<br>**3**<br>**35**<br>**38**|_Group_<br>_2024_<br>_No._<br>_3_<br>_33_<br>_36_|**Company**<br>**2025**<br>**No.**<br>**3**<br>**35**<br>**38**|_Company_<br>_2024_<br>_No._<br>_3_<br>_33_|
|---|---|---|---|---|
||||||
|||||_36_|



The number of higher paid employees was: 

||**Group**|_Group_|
|---|---|---|
||**2025**|_2024_|
||**No.**|_No._|
|£60,001 - £70,000|**3**|_2_|
|£70,001 - £80,000|**2**|_3_|
|£80,001 - £90,000|**3**|_4_|
|£90,001 - £100,000|**2**|_3_|
|£100,001 - £110,000|**1**|_1_|
|£110,001 - £120,000|**2**|_1_|
|£120,001 - £130,000|**-**|_1_|
|£130,001 - £140,000|**1**|_-_|
|£140,001 - £150,000|**-**|_1_|
|£160,001 - £170,000|**1**|_1_|
|£240,001 - £250,000|**1**|_1_|
|£350,001 - £360,000|**-**|_1_|
|£380,001 - £390,000|**1**|_-_|



The total cost that is reflected in the above bandings is made up of wages and salaries, social security costs and defined contribution pension scheme contributions. 

Page 26 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **7. Key management personnel** 

|Wages and salaries<br>Social security costs<br>Cost of defined contribution scheme (Note 16)|**2025**<br>**£**<br>**797,971**<br>**119,696**<br>**28,303**<br>**945,970**|_2024_<br>_£_<br>_771,027_<br>_106,402_<br>_19,721_|
|---|---|---|
|||_897,150_|



In addition to the Board of Trustees, there were 3 ( _2024 - 3_ ) key management personnel, 2 ( _2024 - 2_ ) of which accrued benefits under another group entity's defined contribution pension scheme during the period. 

## **8. Trustees' fees** 

|Fees for services provided (see below)<br>Reimbursed travel expenses paid to 1 trustee|**2025**<br>**£**<br>**21,398**<br>**-**<br>**21,398**|_2024_<br>_£_<br>_26,470_<br>_269_|
|---|---|---|
|||_26,739_|



The highest paid Trustee received remuneration of £NIL ( _2024 - £NIL_ ). 

A Charlesworth, Trustee, received fees for services provided during the period of £14,398 ( _2024 - £13,606_ ). 

R Tarricone, Trustee, received fees for services provided during the period of £7,000 _(2024 - £NIL)_ . 

M Kyle, Trustee, received fees for services provided during the period of £NIL _(2024 - £12,864)_ . 

The fees paid to the two Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its' objectives. 

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party. 

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period. 

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association. 

Page 27 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **9. Tangible fixed assets** 

## **Group and Company** 

|**Cost or valuation**<br>At 1 January 2025<br>At 31 December 2025<br>**Depreciation**<br>At 1 January 2025<br>Charge for the year<br>At 31 December 2025<br>**Net book value**<br>At 31 December 2025<br>_At 31 December 2024_|**IT software**<br>**£**<br>**47,685**|
|---|---|
||**47,685**|
||**30,465**<br>**15,895**|
||**46,360**|
||**1,325**|
||_17,220_|



## **10. Debtors** 

|**Due within one year**<br>Trade debtors<br>Amounts owed by group undertakings<br>Other debtors<br>Prepayments and accrued income|**Group**<br>**2025**<br>**£**<br>**1,456,008**<br>**-**<br>**7,238**<br>**895,252**<br>**2,358,498**|_Group_<br>_2024_<br>_£_<br>_2,010,319_<br>_-_<br>_54,249_<br>_660,352_<br>_2,724,920_|**Company**<br>**2025**<br>**£**<br>**164,753**<br>**2,415,112**<br>**7,238**<br>**455,631**<br>**3,042,734**|_Company_<br>_2024_<br>_£_<br>_185,788_<br>_1,597,341_<br>_54,249_<br>_230,497_<br>_2,067,875_|
|---|---|---|---|---|



Page 28 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **11. Creditors: Amounts falling due within one year** 

|Trade creditors<br>Amounts owed to ultimate parent<br>Other taxation and social security<br>Other creditors<br>Accruals and deferred income<br>Deferred income at the beginning of the year<br>Resources deferred during the year<br>Amounts released from previous periods<br>**Deferred income at the end of the year**<br>**Financial instruments**<br>**Financial assets**<br>Financial assets measured at fair value<br>through income and expenditure<br>Financial assets measured at amortised cost<br>**Financial liabilities**<br>Financial liabilities measured at cost less<br>impairment|**Group**<br>**2025**<br>**£**<br>**44,024**<br>**1,684,993**<br>**4,346**<br>**3,047**<br>**1,742,249**<br>**3,478,659**<br>**Group**<br>**2025**<br>**£**<br>**880,844**<br>**1,389,267**<br>**(880,844)**<br>**1,389,267**<br>**Group**<br>**2025**<br>**£**<br>**3,344,965**<br>**2,329,146**<br>**5,674,111**<br>**Group**<br>**2025**<br>**£**<br>**2,291,392**|_Group_<br>_2024_<br>_£_<br>_61,287_<br>_578,890_<br>_4,678_<br>_43,000_<br>_1,181,328_<br>_1,869,183_<br>_Group_<br>_2024_<br>_£_<br>_581,655_<br>_880,844_<br>_(581,655)_<br>_880,844_<br>_Group_<br>_2024_<br>_£_<br>_694,601_<br>_2,012,754_<br>_2,707,355_<br>_Group_<br>_2024_<br>_£_<br>_988,339_|**Company**<br>**2025**<br>**£**<br>**27,432**<br>**1,623,249**<br>**4,346**<br>**3,047**<br>**484,468**<br>**2,142,542**<br>**Company**<br>**2025**<br>**£**<br>**111,904**<br>**337,687**<br>**(111,904)**<br>**337,687**<br>**Company**<br>**2025**<br>**£**<br>**1,122,611**<br>**3,013,381**<br>**4,135,992**<br>**Company**<br>**2025**<br>**£**<br>**1,804,854**|_Company_<br>_2024_<br>_£_<br>_47,657_<br>_517,369_<br>_4,678_<br>_2,310_<br>_251,015_<br>_823,029_<br>_Company_<br>_2024_<br>_£_<br>_57,369_<br>_111,904_<br>_(57,369)_<br>_111,904_<br>_Company_<br>_2024_<br>_£_<br>_305,491_<br>_1,785,564_<br>_2,091,055_<br>_Company_<br>_2024_<br>_£_<br>_711,125_|
|---|---|---|---|---|



## **12. Financial instruments** 

Page 29 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **12. Financial instruments (continued)** 

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents. 

Financial assets measured at amortised cost compromise of debtors falling due within one year, excluding prepayments. 

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income. 

## **13. Provisions** 

## **Group** 

|Additions|**Provisions**<br>**£**<br>**202,000**|
|---|---|
|||
||**202,000**|



Included within the provisions balance at the year end is an amount for ongoing legal related matters. 

## **14. Reconciliation of net movement in funds to net cash flow provided by operating activities** 

|Net surplus for the year (as per Statement of Financial Activities)<br>**Adjustments for:**<br>Depreciation charges<br>Decrease/(Increase) in debtors<br>Increase in creditors<br>Interest received<br>**Net cash provided by operating activities**|**Group**<br>**2025**<br>**£**<br>**456,571**<br>**15,895**<br>**366,422**<br>**1,811,476**<br>**(22,849)**<br>**2,627,515**|_Group_<br>_2024_<br>_£_<br>_474,894_|
|---|---|---|
|||_15,895_<br>_(845,541)_<br>_389,960_<br>_(16,745)_|
||||
|||_18,463_|



Page 30 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **15. Cash and cash equivalents** 

|Cash at bank and in hand<br>**Total cash and cash equivalents**|**Group**<br>**2025**<br>**£**<br>**3,344,965**<br>**3,344,965**|_Group_<br>_2024_<br>_£_<br>_694,601_|
|---|---|---|
||||
|||_694,601_|



## **16. Analysis of changes in net debt (Group)** 

|Cash at bank and in hand|**At 1**<br>**January**<br>**2025**<br>**£**<br>**694,601**<br>**694,601**|**Cash flows**<br>**£**<br>**2,650,364**<br>**2,650,364**|**At 31**<br>**December**<br>**2025**<br>**£**<br>**3,344,965**|
|---|---|---|---|
||||**3,344,965**|



## **17. Pension commitments** 

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable to the fund, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £192,828 _(2024 - £192,525)_ for the group and £57,899 ( _2024 - £61,077_ ) for the company. 

## **18. Related party transactions** 

During the period two Trustees received fees for services totalling £21,398 ( _2024 - £26,470_ ) (refer to Note 8 for details). At the balance sheet date, no amount ( _2024 - £Nil_ ) of this was outstanding. 

During the period the company received research grants totalling £100,000 ( _2024 - £150,000_ ) from the ABPI. 

During the period, the group and company incurred support costs totalling £395,592 and £115,456 respectively ( _2024 - £443,280 and £208,350_ ), which were recharged by the ABPI (refer to Note 19 below). 

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred as a qualifying charitable donation via Gift Aid (refer to Note 20 below). 

Page 31 



Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F 

## **THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025** 

## **19. Ultimate parent undertaking and controlling party** 

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. 

## **20. Principal subsidiaries** 

The following was a subsidiary undertaking of the company: 

|**Name**|**Country of Incorporation**|**Principal activity**|**Holding**|
|---|---|---|---|
|OHE Consulting Limited|United Kingdom|Provision of policy and|**100%**|
|||strategic expertise on||
|||healthcare and related||
|||matters.||



During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £4,414,549 ( _2024 - £4,204,016_ ), and incurred expenditure totalling £3,312,806 ( _2024 - £2,602,333_ ), plus interest received of £17,729 _(2024 - £13,255_ ), generating profits for the period of £1,119,472 ( _2024 - £1,614,938_ ). OHE Consulting Limited elected to transfer its profits to the company by way of a qualifying charitable donation via Gift Aid, leaving aggregated assets in OHE Consulting Limited of £1 at the period end. 

## **21. Post balance sheet events** 

There have been no significant events affecting the group since the year-end. 

Page 32 

